Manipulation and Biological Applications of Gold Nanorods by Rostro-Kohanloo, Betty Catalina
RICE UNIVERSITY 
Manipulation and Biological Applications of Gold Nanorods 
by 
Betty Catalina Rostro-Kohanloo 
A THESIS SUBMITTED 
IN PARTIAL FULLFILLMENT OF THE 
REQUIREMENTSFORTHEDEGREE 
Doctor of Philosophy 
APPROVED, THESIS COMMITTEE: 
J a n H. Hafn , Chair, Associate 
Professor of Physics and Astronomy 
and Chemistry 
Sibani Lisa Biswal, Assistant 
Professor in Chemical and 
Biomolecular Engineering 
~ ----------1 d." V0( Jellllte~bel C. Cameron 
Professor of Bioengineering and 
Chair, Bioengineering 
HOUSTON, TEXAS 
DECEMBER 2010 
ABSTRACT 
Manipulation and Biological Applications of Gold Nanorods 
by 
Betty Catalina Rostro-Kohanloo 
This thesis compared anionic polyelectrolyte wrapping stabilization with 
poly(sodium 4-stryene-sulfonate), (PSS), polyelectrolyte and methoxy (polyethylene 
glycol)-thiol (mPEG(sooo)-SH) strategies. From this data the critical gold nanorod (GNR) 
and cetyl-trimethylammonium bromide (CTAB) concentration ratio needed for GNR 
stabilization was determined using optical and chemical extraction methods. This was 
followed by functionalization with a heterobifunctional Polyethylene glycol (PEG) linker, 
such as a-thio-w-carboxy poly(ethylene glycol) termed t-PEG-c and carbodiimide 
chemistries for antibody linkage with Immunoglobulin G (IgG), and epidermal growth 
factor receptor (EGFR) based Human Epidermal growth factor Receptor 2 (Her2), and 
Cetuximab (C225) antibodies, for in vitro cancer cell targeting. Confocal, two-photon 
luminescence (TPL), and dark scattering microscopy, and fluorescence, zeta potential, 
and Nanoparticle Enzyme-linked immunosorbent assay (ELISA) were used to monitor 
changes to the GNR surface. An untreatable form of bladder cancer was then studied 
using the t-GNR-PEG-c-Ab bioconjugates with C225 antibody, which housed a 
glyceraldehyde-3-phosphate (GAPDH), Fluorescein isothiocyanate (FITC) labeled 
siRNA, termed GAPDH-siRNA-FITC, which was included within a Luciferase based 
plasmid. A salt based electrostatic heating method was used to trap the GAPDH-siRNA-
II 
FITC from the PEG layer by activating the PEG polymer pour point, while a laser based 
heating system was used for in vitro release inside cancer cells. The down regulation of 
the GAPDH gene was targeted by the siRNA, as GAPDH has been shown to be up-
regulated in many cancers and down-regulated by chemotherapeutic drugs. Cell culture, 
and subsequent imaging by transmission electron microscopy (TEM), TPL and confocal 
microscopy were used to view the internalized conjugates, and reverse transcriptase 
polymerase chain reaction (RT-PCR) were used to determine if the release of the 
GAPDH-siRNA caused a reduction in the expression of GAPDH-mRNA. Plasmonic 
gene silencing of the gene by the GAPDH-siRNA was then compared to a lipid based 
Dharmafect control in terms of transfection ability. RT-PCR results evidenced gene 
silencing of the plasmonic-GAPDH-siRNA vector when compared to the Dharmafect 
control. Silencing likely resulted from the zwitterionic charges of the plasmonic vector 
and the encapsulated GAPDH-siRNA, which yielded near neutral charge tendencies. 
This differs significantly from the Dharmafect lipid vector, which is cationic in nature. 
Endosomal release of the plasmonic vector is further enhanced by the laser excitation of 
the GNR at the longitudinal surface plasmon resonance (LSPR), which allows for the 
endosomal release of the GAPDH-siRNA through pore formation leading to cytoplasmic 
transport and subsequent gene silencing. Near neutral charges were welcomed in this 
plasmonic gene therapy study as they tend to favor endosomal release, pore formation, 
and transport. 
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CHAPTER! 
Plasmon Resonances 
Reducing the size and dimensionality of a material can affect its interactions with 
electromagnetic radiation, as well as its surface chemistry. 1-3 In noble metal particles that 
are much smaller than the wavelength of incident light, the surface properties of the 
material govern interactions at visible and near-infrared (NIR) wavelengths, and lead to 
the ability to manipulate light at the nanometer scale. The gold nanoparticles that are the 
subject of this work manipulate light through resonant collective oscillations of the 
conduction electrons, termed localized surface plasmon resonances, which result in 
strong optical absorption and scattering.2-6 This exotic behavior can be seen in the 
reddish-orange hues of stained glass windows in many medieval churches and in the 
Lycurgus Cup from the 4th century AD. The presence of colloidal gold in the glass 
absorbs the green wavelength of light, producing a deep ruby red in transmitted light, as 
shown in Figure 1-1. 10 
1 
Figure 1-1. a) Stained glass and, b) Lycurgus cup colored with colloidal gold 
nanoparticles that yields unusual optical properties. 
1.1 Nanoparticle Analysis 
1.1.1 Plasmons 
When light strikes the metal nanoparticles, it creates an electromagnetically 
induced oscillation of the conduction electrons in the particles. The restoring force, 
2 
which is the Coulombic attraction of the electrons towards the nuclei in the lattice, 
creates a resonant condition within a relatively narrow spectral band termed a localized 
surface plasmon resonance. 8 Excitations of the surface plasmons generate large local 
fields within the vicinity of the nanoparticle surface, which strongly exceed the intensity 
of the incident light field. This produces enhanced optical phenomena at the nanoparticle 
surface such as fluorescence, Raman scattering, second-harmonic generation, and other 
non-linear optical responses. The plasmon resonance also results in enhanced absorption 
and scattering of incident light by the nanoparticles. The type of metal, its size, and 
geometry will ultimately dictate the strength and peak wavelength of these effects. 
Noble-metal gold and silver nanoparticles have small losses at the optical frequencies, 
and tend to exhibit strong resonant behavior, with the resonance of silver being stronger 
than that of gold. 4-5 Plasmon resonances cause a peak in the spectral extinction of 
nanoparticle solutions, as seen in Figure 1-2. 
The observed reddish-purple hues of spherical gold nanoparticle solutions result 
from a strong absorption band centered around 520 nm (2.3 e V), which is when the 
frequency of the electromagnetic field of the incoming light is resonant with the 
collective oscillation of the conduction electrons. I.4-5 We will discuss gold nanoparticles 
of 10 nm through 60 nm in diameter, where the dissipation regime of the plasmon decay 
dominates the dephasing of the collective electron motion, and reradiation, which is 
present in larger particles, is highly diminished. 1-5 We will discuss these absorbing 
particles and their subsequent plasmons, shape dependence, functionalization with 
polymers, and their biological applications such as cell targeting, internalization, cell 
receptor specific binding, and gene therapies. 
3 
1.1.2 GNR Shape 
If the nanoparticle shape is significantly altered it will have a tremendous affect 
on the plasmon absorption band. 13-15 The boundary conditions of the gold nanoparticles 
affect the coherent electron oscillations and the interband d to sp electronic transitions, 
which in turn affect the optical absorption properties. Nanoparticle size also affects the 
resonance frequencies and width of the plasmon absorption band. Altering the shape and 
size of such nanoparticles gives control over spectral variations in how the captured 
electromagnetic energy is distributed.12 Gold nanorod(s), (GNR), support a large 
absorption cross-section at NIR frequencies per unit volume when compared to other 
nanostructures and have narrower linewidths due to reduced radiative damping effects, 
with higher optothermal conversion efficiencies. For GNR the plasmon absorption band 
is split into two bands, transverse and longitudinal, these stemming from the oscillation 
of free electrons along and perpendicular, to the long axis of the rods, Figure 1-2, Figure 
1-3.4-6· 12 The transverse band of the GNR occurs at a wavelength of 520 nm, note that this 
is also seen in spherical nanoparticles. The longitudinal plasmon band, can red shift into 
the NIR, and is approximately linear with aspect ratio, and with the dielectric function of 
the medium. 2 The aspect ratio of the GNR can be tailored by varying the ratios of 
surfactants to cosurfactant molecules during their synthesis. 13-15 
The width and height of the plasmon band is directly related to the associated 
decay mechanisms of the electrons which occur due to the dephasing of the collective 
electron motion arising from radiative damping, and electron scattering, off phonons and 
4 
defects. 1-3 Due to the longitudinal localized surface plasmon resonance (LSPR), 
nonlinear optical effects can also arise. Two-photon absorption can also present itself in 
the GNR, due to an electronic transition from the d- to sp-bands, leading to an electron-
hole pair. Recombination of the separated charges would then result in two-photon 
luminescence (TPL) emission. The conversion of optical energy into heat arises from the 
nonradiative electron relaxation dynamics, which creates the resulting electron-phonon 
collisions. This provides gold nanoparticles with photothermal properties such as 
localized heating that can be of use in medical therapeutics and biomedical imaging. 
1.1.3 Mie Theory 
Mie was the first to explain the surface plasmon resonance behavior of spherical 
metal nanoparticles by solving Maxwell's equation for the interaction of an 
electromagnetic plane wave with an interacting small sphere. 1-12 It then became possible 
to calculate a particle's extinction spectrum by simply using the material's dielectric 
function. 4-5 The total extinction coefficient of the metal nanoparticles was taken to be 
the summation over electric and magnetic multipole oscillations, which would contribute 
to the absorption and scattering of the interacting electromagnetic field. Nanoparticles 
that are well below the wavelength of light, these being particles that are smaller than 100 
nm, show a strong contribution from the dipole oscillation, and so only this term is 
relevant when tabulating the absorption spectra.4-5 
In the quasi-static regime the plasmon resonant extinction can be tabulated by 
using Equation 1-1, where K is the extinction coefficient, for N particles of volume V. Bm 
is the dielectric constant of the medium, A is the radiation wavelength, s1 is the real part 
5 
of a material's dielectric function, 82 is the imaginary part of a material's dielectric 
function.5 
(Equation 1-1) 
The materials dielectric function can in turn be expressed as a summation of 81 and 82, 
where co is the angular frequency oflight, this is given in Equation 1-2.1-12 
(Equation 1-2) 
In order to tabulate the absorbance of a colloidal solution containing N particles in an 
optical cell of path length L, you would take the extinction coefficient, K and use 
Equation 1-3.5 
A ·(KjtniO}L (Equation 1-3) 
Noble metal nanoparticle have small, negative E1 in the visible, and a small 82, which are 
responsible for their sharp plasmon resonances. 2•5 The resonance condition for the 
plasmon absorption band is fulfilled when E1(ro)=-2Em. While the minimum plasmon 
bandwidth depends on E2, it is also size dependent. 2•5 
1.1.4 Gans Theory 
These shifts in the plasmon wavelength, which are altered with respect to shape 
and environment, can be calculated by Gans' theory, which is a more modified form of 
Mie theory.4-6 The extinction coefficient, K, shown in Equation 1-4 is given in terms of 
the number of particles N, volume V, P1 depolarization factors, whereby the material 
dielectric constant 8m is frequency independent, and 8 1 and 82 are the real and imaginary 
part of a material's dielectric function. 4-6 
6 
(Equation 1-4) 
The depolarization factors for axes A, B, C, are shown as PA and PB=Pc, with the aspect 
ratio, R, and A., which is the radiation wavelength, are then used to tabulate the extinction 
coefficient, this is shown in Equation 1-5.4"6 
P4 - l-t' [-L. tn( ~ .. +e)- 1] 
e 2e d-e, 
1- p p .p- ........ 4. 
IJ • 2 (Equation 1-5) 
! (B)! 1 
e • ti I - - - ,,. 1 - -
' ,AI , R: 
where Pi are depolarization factors for axes A, B, C, where A > B = C for a prolate 
spheroid. 
1.1.5 Analysis 
For GNR, their aspect ratio is tabulated in terms of the ratio of the length and 
width of the rod, where the average nanorod length is 44 run and width is 11 run, these 
being parameters that were determined by Atomic Force Microscopy (AFM), and 
Scanning Electron Microscopy (SEM), this is shown in Figure 1-2. This can be 
compared to the calculated absorption spectrum shown in Figure 1-3. Aggregated GNR 
and other nanoparticles will show a red-shifted plasmon absorption band and longer 
wavelengths, due to the nanoparticles being electronically coupled. 2 This occurs since the 
oscillating electron in one particle will feel the electric field due to the oscillating free 
electron in a second particle, which is a short distance away, leading to a collective 
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plasma oscillation of aggregated particles. The frequency and intensity of the resulting 
band will be determined by the degree of aggregation, orientation of nanoparticles, and 
interparticle coupling. 2 
0.7 
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Figure 1-2. AFM of 20 nm by 45 nm GNR (background) and HiVac SEM (overlay) 
and LSPR bands that are optically evident (right). 
600 800 1000 
Wavelength (nm) 
Figure 1-3. A comparison of the extinction spectrum calculated for prolate spheroids 
(Gans theory) and gold nanorods (experiment). 
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1.2 Conclusion 
Noble metal particles are much smaller than the wavelength of incident light, and 
their material surface properties govern interactions at visible and NIR wavelengths, 
which lead to the ability to manipulate light at the nanometer scale. The gold 
nanoparticles can then manipulate light through resonant collective oscillations of the 
conduction electrons, which are LSPR that result in strong optical absorption and 
scattering, at visible and NIR wavelengths. These shifts in the plasmon wavelength, 
which are altered with respect to shape and environment, can be calculated by Gans' 
theory, which is a more modified form ofMie theory, and are dependant on the material's 
dielectric function and the particle's environment. This can be of considerable interest in 
biomedical applications, since the plasmon resonances can affect localized heating and 
light scattering, which can benefit biological systems that require relatively inert gold 
nanoparticle based therapies. To date tunable gold nanoparticles have already been 
implemented in applications ranging from photothermal therapies, drug delivery, and 
diagnostic imaging which make use of the nanoparticle shape biased LSPR.73-79 
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CHAPTER2 
Gold Nanorod Stabilization 
CT AB, which is needed for the synthesis and stability of the GNR, produces 
various unwanted effects for biological GNR applications due to its cytotoxicity and 
nonspecific binding.16"18 The CTAB plays an important role in determining the 
aggregation behavior of GNR, for example, high CT AB concentrations serve as a 
stabilizer that prevents nanorod agglomeration. CT AB is beneficial in that it imparts the 
rods with a positive charge, leading to repulsive forces that electrostatically stabilize the 
GNR against the attractive van der Waals forces of the bare metal, which is thought to 
occur through the formation of CTAB bilayers on the surfaces. 19"21 •23•72 This helps in 
offsetting the GNR aggregation behavior by preventing the bare gold surfaces of the rods 
from binding to each other. 19"21 Lowering the CTAB concentration leads to a loss of 
bilayers often leading to immediate GNR aggregation?4-36•72 The strong binding of 
CT AB-gold surfaces, and the resulting slow exchange at the GNR surface, has led to 
extensive surface modification and functionalization techniques that can displace or 
overcoat the CT AB and stabilize the GNR. Yet, the strong CTAB-gold absorption 
continue to make such techniques a significant challenge.24•26 
2.1 GNR Surface Modification 
In order to overcome such problems several strategies have been developed to 
modify the surface chemistry of the GNR in order to either bind and/or displace the 
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CTAB surfactant layer. Some groups have used electrostatic polymer methods to bind 
the CTAB layers through wrapping with anionic polyelectrolytes like polyaspartic acid 
(P AA), while others have focused on displacing the CTAB layer using thiol-terminal 
polyethylene glycol (tPEG) functionalization strategies.30"31'3444 Other strategies have 
focused on experimenting with displacement with alkanethiols, and lipids, however, all of 
these strategies must be studied further, as reproducibility issues still arise.32"33 In this 
study, a suitable method to overcome such issues was developed through the use of 
previously described poly(sodium 4-stryene-sulfonate) (PSS) polyelectrolyte wrapping 
methods and compared this to (polyethylene glycol)-thiol (mPEGcsooo)-SH) strategies. 
Here we identify the sensitivity of GNR to CT AB concentration and determined the 
critical GNR/CT AB concentration ratio which was needed for CT AB stabilization. A 
comparison of electrostatic polymer wrapping to covalent mPEGcsooo)-SH stabilization 
through water dilution, chloroform extraction, and optical characterization techniques 
provided the critical CTAB concentration that was needed for GNR stability. 
2.2 Methods 
2.2.1 GNR synthesis 
GNR were prepared using the seed-mediated synthesis, and scaled up to increase 
the quantity.80"82 Gold seed particles were prepared by adding 250 1-1L of 10 mM 
HAuC14•3H20 (Sigma, #520918) to 7.5 mL of 100 mM CTAB (Sigma, #H9151) with 
brief, gentle mixing by inversion. To this was immediately added 600 1-1L of freshly 
prepared, ice-cold 10 mM NaB~ (Acros, #H9151) solution (2-8°C), followed by mixing 
by inversion for 2 minutes, leading to a pale brown seed solution that was stable and 
usable for several days. The nanorod growth solution was prepared in a plastic tube, by 
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adding the following reagents in the order given, 425 mL of 100 mM CTAB, 18 mL of 
10 mM HAuCl4•3H20, 2.7 mL of 10 mM AgN03 (Acros, #19768), and then gently 
mixed by inversion. To this mixture was added 2.9 mL of 100 mM ascorbic acid (Fisher, 
#A61) and mixed by inversion, which changed the solution from a brown-yellow to a 
clear colorless solution. GNR growth was initiated by adding 1.8 mL of the seed solution 
to the growth solution, which was followed by gentle mixing. The solution was then 
incubated for 3 hours at room temperature, which produced a color change to dark purple, 
mostly within the first hour. This dark purple color change is representative of GNR 
growth. 
2.2.2 PSS stabilization 
GNR solutions were heated to 30°C to melt CTAB crystals which form at room 
temperature, leading to a known initial CT AB concentration of 100 mM. 5 mL aliquots 
were pelleted by centrifugation at 10,000 RPM (6,800 ref) for 60 minutes. 4.5 mL of the 
clear supernatants were decanted, and the pellets were resuspended with deionized (DI) 
water. The GNR solutions were pelleted again at 10,000 RPM (6,800 ref) for 60 minutes, 
and the clear supernatants were decanted. For anionic polymer stabilization, the GNR 
pellets were resuspended with 4.5 mL of a solution containing 30 mg/mL poly(sodium 4-
stryene-sulfonate) (PSS, Aldrich, #243051) and 1 mM NaCl. The GNR solution was 
incubated overnight at room temperature. 
2.2.3 Thiol-terminated PEGylation (mPEG-SH) 
GNR solutions were heated to 30°C to melt CT AB crystals which form at room 
temperature, providing a known initial CT AB concentration of 100 mM. 5 mL aliquots 
were pelleted by centrifugation at 10,000 RPM (6,800 ref) for 60 minutes. 4.5 mL of the 
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clear supernatants were decanted, and the pellets were resuspended with water. The 
GNR solutions were pelleted again at 10,000 RPM (6,800 ref) for 60 minutes, and the 
clear supernatants were decanted. For PEGylation, the GNR pellets were resuspended 
with 4.5 mL of a solution containing 200 !lM K2C03 and 10 !lM methoxy (polyethylene 
glycol)-thiol (mPEG(sooorSH) (Nektar Therapeutics, #2M4EOH01) in DI water. The 
GNR solution was incubated overnight at room temperature. 
2.2.4 Chloroform Extraction 
To study the dependence of the effect of GNR stabilization with CTAB 
concentration, a chloroform extraction of CT AB was performed. CTAB was extracted 
from the 10 mL nanorod solution using a separatory funnel and 100 mL of chloroform. 
The mixture was vigorously shaken and allowed to separate overnight, while the aqueous 
nanorod solution was extracted and 500 IlL aliquots were placed in the test tubes. To 
theses test tubes, increased chloroform aliquots were added from 0, 50, 100, 150, 200, 
250, and 300 IlL After vigorous mixing, the samples were allowed to separate 
overnight, the following day the solutions were removed and analyzed. 
2.2.5 GNR Optical Data 
Subsequent rounds of centrifugation at 10,000 RPM (6,800 ref) for 60 minutes, 
greater than 95% decantation, and resuspension with DI water were carried out on the 
CTAB stabilized nanorods (CTAB-GNR), PSS stabilized nanorods (PSS-GNR), and 
PEGylated nanorods (mPEG-GNR). At each round, the supernatant was replaced by DI 
water in such a way as to reduce the CTAB concentration by a factor of 10. The 
extinction spectra were recorded at each stage, and the LSPR peak wavelength, peak 
width, and peak height were recorded and plotted. 
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2.2.6 GNR mass spectrometry 
The MALDI-TOF mass spectrum was taken on a Brunker MS Reflex IV MALDI-
TOF. DCTB (trans-2-[3-( 4-tert-Butylphenyl)-2-methyl-2-propenylidene] malononitrile) 
was used as the matrix, solvents were removed by lyophilization using a SpeedVac. 
2.3 Results and Discussions 
2.3.1 PEGylation -vs.- Polyelectrolyte Stabilization 
To characterize the critical CTAB concentration, the LSPR spectrum ofthe GNR 
solutions was monitored by sedimentation. In order to determine the critical CT AB 
concentration that was needed for GNR stability, GNR solutions were heated to melt the 
CTAB crystals, which provided a well-defined initial concentration of 100 mM. 
Subsequent rounds of sedimentation by centrifugation, 90% decantation, and 
resuspension with DI water were carried out on CTAB stabilized nanorods (CTAB-
GNR), PSS stabilized nanorods (PSS-GNR), and mPEG(sooo)-SH stabilized GNR (mPEG-
GNR). At each round, the supernatant was replaced by DI water in such a way as to 
reduce the CT AB concentration by a factor of 10, leading to a negligible quantity of 
CTAB that is bound to the GNR surface compared to the initial CTAB concentration. 60 
The extinction spectra were recorded at each stage, and the LSPR peak wavelength, peak 
width, and peak height were recorded and are plotted in Figure 2-1. 
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Figure 2-1. The evolution of the plasmon resonant peak of nanorod solutions after 
reduction of the CT AB concentration by sedimentation. The absorbance peak height 
(top), peak wavelength (middle), and peak width (bottom) for CTAB-GNR (A), anionic 
PSS-GNR (v), and mPEG<sooo)-GNR (0"). 
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LSPR peak height reduction, broadening, and red shifting were observed around 
the third round of sedimentation, which suggested GNR aggregation. This aggregation 
was noted during the third round of centrifugation, which is when the CT AB 
concentration is around 1 to 0.1 mM. Both polyelectrolyte PSS and mPEGcsooo)-SH 
stabilized the GNR against lower CT AB concentrations. The mPEGcsooo)-SH, however, 
evidenced reduced aggregation when compared to PSS polyelectrolyte. PSS is a strong 
polyanion polyelectrolyte that is thought to wrap the cationic CTAB bilayer and stabilize 
the nanorods by electrostatic interparticle repulsions.27-47 PSS polyelectrolyte 
electrosteric stabilization requires the adsorption of charged polyelectrolyte that wraps 
the CTAB, yielding both electrical double layer repulsive forces and a steric barrier.45-46 
Since PSS is more strongly bound than CTAB, it does not require a bulk concentration of 
PSS in solution, which is required for CT AB. The PSS yield for stabilization was only 
about 50% based on the height of the LSPR absorbance peak (from 3 to 1.5). It resulted 
in a small red shift, but significant increase in peak width indicates some level of GNR 
aggregation. 
The mPEGcsooo)-SH also stabilized the GNR, through the covalent attachment of 
polymeric chains around the particles forming a sterically protective layer.47 Rather than 
wrapping, the mPEGcsooo)-SH displaces the CT AB layer to directly form a covalently 
bound gold-thiol polymer film on the GNR surface.46-48 Once PEGylated, the GNR 
surfaces do not come into contact due to simple steric interference. The less dense 
packing stemming from the binding of the thiol-PEG polymer chains provides a steric 
barrier which offsets interparticle GNR interactions. This is distinct from the role of 
PEGylation in stabilizing nanoparticles and drugs in vivo, where it shields the PEGylated 
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object from the immune system. PEGylation is superior to polyelectrolyte wrapping 
based on Figure 2-1. The yield remains above 67%, and the red shift and peak 
broadening are negligible indicating no significant GNR aggregation. In addition, the 
covalent GNR stabilization by mPEG(sooo)-SH will be stable over a wider range of pH 
conditions than electrostatically CT AB stabilized GNR or PSS-GNR. Further evidence 
of the improved monodispersity of PEG stabilized nanoparticles can be seen by 
comparing films produced with mPEG(sooo)-SH nanoparticles versus those produced with 
polyelectrolyte-stabilized particles. 30-31 
2.3.2 GNR stability against sedimentation 
Below a 1 00 f.!M CT AB concentration, the GNR begin to experience significant 
aggregation. This value is, however, much larger than that required to coat the nanorod 
surfaces. The GNR surface area is: 
area== nd l + 2n(d/2) 2 
1) 
(Equation 2-
neglecting the spherical shape of the end caps.83 For a typical nanorod of 15 nm diameter 
and 50 nm length, the area is 2708 nm2. Given a typical CTAB headgroup area of 0.3 
nm2, and the fact that the CTAB is thought to form a bilayer, one would expect 
approximately 9000 CT AB molecules per nanorod. Given that the GNR concentration is 
approximately 0.2 nM, the effective concentration of the CTAB that actually covers the 
nanorods is only 1.8 f.!M. Since that is much smaller than the required solution 
concentration, it is clear that there is significant exchange between the CT AB molecules 
on the nanorod and those in solution. Also, the critical concentration for nanorod 
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stability, 100 JlM, is near typical values of the critical micelle concentration for charged 
surfactants. 
2.3.3 GNR stability against dilution 
In addition to sedimentation, the GNR stability against water dilution was tested. 
The CTAB concentration was reduced by slow dilution with DI water directly in a 
cuvette. The spectra were monitored during dilution, and the peak wavelength, height, 
and width results are shown in Figure 2-2. One can see that there is no sign of 
aggregation even to a CT AB concentration of 50 JlM, which apparently contradicts the 
results of Figure 2-1. This contradiction can be explained if one considers that it is not 
the absolute CT AB concentration that is important, but the ratio between the CT AB and 
GNR concentrations. When diluting the GNR and CT AB solutions with water, the peak 
height underwent a linear decrease due to dilution of the nanorods. We observed no 
significant peak wavelength shift and no peak broadening, so the nanorods did not 
aggregate. The lack of aggregation to 50 JlM suggests that it is the ratio of CT AB to GNR 
concentration that critically determines stability, rather than the CT AB concentration 
alone. However there are various thermally induced effects that can often interfere with 
the optical response of GNRs. These include heating of the CTAB and water molecules 
that surround the GNRs, which often results in their thermal activation and subsequent 
migration away from the GNR surface. Such thermal effects can interfere with the GNR 
optical signals often producing changes to the refractive index, and shifts to the LSPR 
bands. 
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Figure 2-2. Aggregation based on CT AB concentration, with water dilution the CT AB 
concentration drops, but no aggregation is evidenced, this suggests that CT AB/particle 
loading ratios determine aggregation behavior. 
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2.3.4 GNR stability against extraction 
Sedimentation is not effective as a means to adjust the CT AB/GNR concentration 
ratio. Upon sedimentation, the nanorods form a pellet that spikes the GNR concentration 
before the pellet is diluted. To more controllably alter the CTAB/GNR concentration 
ratio, we extracted the CT AB with chloroform. Since the nanorods remain in the aqueous 
phase, the CTAB/GNR ratio is gently lowered as the CT AB concentration lowers. The 
results of the chloroform extraction are shown in Figure 2-3. Note that the GNR 
aggregate suddenly as the CT AB concentration in reduced by the addition of increasing 
0 ~L 
chloroform volume. 
100 ~L 150 ~L 200 ~L 300 ~L 
Figure 2-3. A photograph of 500 J.!L nanorod solutions that were extracted with the 
stated volume of chloroform. 
To quantitatively determine the critical CTAB/GNR concentration ratio for GNR 
stability, the distribution ratio of CTAB between water and chloroform was measured to 
be approximately 4. The experiment was repeated and the chloroform volume was 
carefully adjusted to find the exact concentration at which the GNR aggregate. Figure 2-
4 displays LSPR spectra of a GNR solution at two CT AB concentrations adjusted by 
chloroform extraction. 
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Figure 2-4. The LSPR extinction spectra of nanorod solutions at two CT AB 
concentrations achieved by chloroform extraction. The nanorod concentration was 0.5 
nM. 
With this precise critical CT AB concentration, the critical CT AB/GNR 
concentration ratio can be calculated. Since the GNR concentration was at 0.5 nM, when 
the CTAB concentration was 370 J.!M the ratio of CTAB/GNR was 740,000, and when 
the CT AB concentration was 290 J.!M, the ratio of CTAB/GNR was 580,000. So, 
according to the spectra in Figure 2-4, aggregation occurs rapidly at a critical 
CTAB/GNR ratio of 740,000. This large ratio further confirms that the CTAB 
concentration required for stabilization is much greater than that required to simply cover 
the GNR, and that the [CTAB]/[GNR] ratio is critical for GNR stability due to the 
dynamic interactions between CT AB in solution and the bilayer. 
As shown above, the exact CT AB concentration that is needed for GNR stability 
will depend on many parameters that are not usually well controlled, these include the 
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GNR concentration and initial CT AB concentrations that vary with particle surface area. 
These results highlight the widely varying reports regarding the amount of CT AB 
required to stabilize gold nanorods. Therefore, the CTAB must be in a dynamic 
equilibrium between the GNR surface, and bulk CT AB micelle solution. Furthermore, the 
CTAB concentration is not usually reduced in a controlled manner since a certain amount 
of CT AB is needed for each GNR, thus requiring a certain CT AB/GNR ratio of adsorbed 
CT AB at the GNR particle, to offset the van der Waals. This is consistent with colloidal 
stability, which requires stabilization agents that provide a repulsive barrier to offset the 
van der Waals forces at the particle surface, which lead to the nanopaiticle aggregation 
tendencies. 
2.3.5 Mass Spec and trace CT AB 
We also studied residual CTAB m the PEGylated GNR samples by mass 
spectrometry (MS), which showed that even after PEGylation and extensive 
washing/decants, some residual CT AB remains bound to the GNR surface. This is 
shown in the mass spectras below, Figure 2-5 and Figure 2-6, where even after 10 
decants a residual [CTAB-Brt ion peak is evident at m/z, 284.53), in the lyophilized 
solutions followed by an Au- peak at m/z, 197.976. Note that the GNR solutions had to 
be lyophilized as the CTAB was not seen in the liquid solutions. This suggested that the 
CTAB-gold interaction is quite strong, that even long PEG incubations and extensive 
rinsing- over 10 cycles of decants, will not entirely remove the adsorbed CTAB. CT AB-
metal surface adsorption can often be weak and completely reversible in metals other 
than gold. Quartz Crystal Microbalance (QCM) studies have shown that the CT AB-gold 
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adsorption is partially irreversible, except upon acid exposure, as this alters the 
surfactant-gold electrostatics. 50 
1000 
Alearblt.Add 
m Au 
1 m.m 1 I d. l lU. l 1 .. 
0 
150 200 250 JOG JSO 
Figure 2-5. MS of the 1st decant of the purification of mPEG (50oo)-SH stabilized GNR 
with [CTAB-Br]+ ion (m/z, 284.213), Au- (m/z, -197.976), and Ascorbic acid (m/z, 
-175), note that PEG is not shown due to the higher molecular weight of the PEG 
polymer chains. 
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Figure 2-6. MS of the 10 decant of the purifcation of mPEG(sooo)-SH stabilized GNR 
with [CTAB-Brt ion (rn/z, 284.10) and Au- (rn/z, -197.983), with no Ascorbic acid 
noted. 
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This suggests that the residual CTAB was trapped within the PEG surface of the 
GNR, and would still be present despite the number of decants and PEG displacement.24 
This is why future studies of the CT AB displacement during the mPEG(sooo)-SH 
functionalization and surface chemistry modification of the GNR are needed.24 However, 
it should be noted that the remaining trace CTAB is likely trapped within the t-PEG layer 
of the GNR, and is at a sufficiently low concentration (below 10 J.!M), which is not 
cytotoxic to cells. In our targeting experiments described in chapters 3 and 4 we have not 
observed any cytotoxic effects associated with PEGylated nanorods that were prepared 
by this method. 
2.3.6 GNR Stabilization Discussion 
The CT AB surfactant, which is needed for GNR synthesis is also needed to 
maintain the colloidal stability of the GNR. The CTAB concentration at which this 
stability is lost has not been well characterized, and stems from a number of factors. 
Since sedimentation, decantation, and resuspension of GNR into pellets is often used to 
reduce the CT AB concentration, lack of analytical techniques in these procedures can 
lead to unknown initial CT AB concentrations. Further, GNR synthesis is carried out in 
100 mM CTAB, which is above the saturation concentration at room temperature. This 
causes the crystallization of the CT AB upon storage, leading to unknown concentrations 
of the surfactant being drawn up from the bulk solution phase. Finally, micellization and 
association of CT AB with gold and silver ions in solution can complicate the analysis, 
i.e. spectroscopic characterization, of the CTAB concentrations. However, below 1 mM, 
CTAB can stabilize the GNR solutions, and this is often perplexing, as decreased 
surfactant concentrations are notable at causing aggregation. Furthermore, the GNR 
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stability has shown to fail at a critical value, since it is the ratio of the CTAB/GNR 
concentration that determines stability, rather than the CTAB alone. This means that for 
a known concentration of a GNR sample, a certain CT AB concentration will be needed, 
since it is the CTAB/GNR ratio which ultimately determines the samples stability. The 
surface area parameters of the GNR are also relevant, as this is what ultimately 
determines the degree of CT AB bilayer formation that is needed to coat the GNR surface. 
This implies that the critical CTAB concentration for a given sample really is determined 
by the GNR size parameters. Such factors can lead to a variability in defining the critical 
CT AB concentration per GNR sample, which often complicates the reproducibility of the 
stabilization and bioconjugation methods. 
A thiol-PEG strategy was then compared to PSS stabilization methods. The GNR 
were stabilized using mPEG<sooo)-SH functionalization, as this can be used to effectively 
displace the CTAB bilayers. This allows the CTAB to be reduced to an arbitrarily low 
concentration suggesting that the PEG is responsible for maintaining GNR stability?0 
PSS stabilization was likewise able to stabilize the GNR as the anionic polymer is 
attracted to the CT AB bilayers, this occurs due to wrapping of the CT AB and the 
formation of multiple polyelectrolyte layers around the CTAB layers.31 Stabilization 
comparison of CTAB-gold nanorods shows significant aggregation following only two 
rounds of centrifugation. mPEG<sooo)-GNR stabilization shows significantly higher 
yields, and narrower LSPR linewidths when compared to electrosteric polyelectrolyte 
stabilization methods and CT AB stabilization. Microscopic characterizations of GNR 
substrates also suggest that PEGylated GNR solutions yield more monodisperse GNR 
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substrates when compared to aggregated polyelectrolyte wrapped GNR glass 
substrates. 30-31 
2.4 Conclusion 
mPEG(sooo)-SH functionalization can displace the CTAB while polyelectrolytes 
can wrap the CTAB present on the surface of the GNR. Chloroform extractions of 
CT AB showed that a critical CT AB/GNR ratio is needed in order to maintain colloidal 
stability of the GNR, this was found to be 740,000:1. Yet in spite of mPEG(sooo)-SH 
covalent functionalization methods, some residual CT AB remains bound to the particles, 
as shown by the MS data. Nevertheless at these CT AB concentrations, which are below 
10 flM, cell cytotoxic effects are typically absent. Both the mPEG(sooo)-SH and PSS 
stabilization methods were effective methods by which to stabilize the GNR. However, 
the mPEG(sooo)-SH covalent functionalization method leads to higher yields and more 
monodisperse GNR samples. 
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CHAPTER3 
Gold Nanorod Bioconjugation 
The physical and chemical nature, surface charge, and nanoparticle size of the 
GNR often makes it difficult to predict their uptake and delivery into cells, tissues, and 
organisms, and is therefore an area that is currently under serious scientific 
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proteins such as antibodies with a heterobifunctional PEG linker, such as a-thio-ro-
carboxy poly(ethylene glycol) which we term t-PEG-c. The t-PEG-c linker allows for 
covalent conjugation strategies to antibodies using zero length carbodiimide chemistries. 
The 1-ethyl-[3-dimethylaminopropyl]carbodiimide (EDC) chemistry allows for a 
hydrophobic C=O from acylisourea to be stabilized with N-hydroxysuccinimde (NHS). 
This stable NHS can then form an amide bond with the antibody, which can then 
facilitate a drug's hydrophobic loading onto the amphiphilic PEG. In this study t-PEG-c 
conjugation strategies were employed to stabilize GNR followed by subsequent 
activation with a stabilized EDC carbodiimide linking agent, and conjugation with 
antibodies ranging from Immunoglobulin G (lgG), Human Epidermal growth factor 
Receptor 2 (Her2), and Cetuximab (C225), for in vitro cancer cell targeting. Conjugates 
with biomolecular targeting ligands of monoclonal antibodies were then used for in vivo 
tumor targeting strategies, and as therapeutic anti-cancer agents. Confocal, two-photon 
luminescence (TPL), and dark scattering microscopy methods coupled with fluorescence, 
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zeta potential, and Nanoparticle Enzyme-linked immunosorbent assay (ELISA) were 
used to monitor changes to the conjugated GNR surface. 
3.1 Methods 
3.1.1 t-GNR-PEG-c Conjugation 
Coming® 15mL clear polyethylene terephthalate (PET) centrifuge tubes with 
maximum RCF of 3,600 x g were initially rinsed out with 50 mM Borate Buffer pH 8.6 
(Pierce #28384) in DI water. A IS-minute incubation in 50 mM Borate Buffer pH 8.6 
was followed by homogenization of the buffer using a Vortex genie for 5 minutes. 
Buffer rinse or use of antistatic devices is highly recommended as this can offset any 
residual static charge that naturally builds up on the PET vial surface. Extra care should 
also be taken to avoid rubbing the vial to the packaging when removing the vial from its 
plastic bag, as this is known to increase static charge that occurs due to low air humidity. 
Reduction of static charge will help decrease the aberrant GNR particle binding to plastic 
walls which can be a major factor in the aggregation of GNR at low CT AB 
concentrations. 
CT AB-GNR stock solutions were heated to 30°C to melt CTAB crystals which 
form at room temperature, and therefore provided a known initial CT AB concentration of 
100 mM. 5 mL aliquots of CT AB-GNR were pelleted by centrifugation at 10,000 RPM 
(6,800 ref) for 60 minutes. 4.5 mL of the clear supernatants were decanted to greater 
than 95%, and the GNR pellets were resuspended with DI water. The GNR solutions 
were pelleted again at 10,000 RPM (6,800 ref) for 60 minutes, and the clear supernatants 
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were decanted to greater than 95% and resuspended in 50 mM Borate buffer pH 8.6, 
leading to a 1 mM CTAB concentration. For t-PEG-c functionalization, the GNR pellets 
were resuspended with 4.5 mL of 50 mM Borate buffer pH 8.6, to which was added 200 
mM of the t-PEG-c linker (Iris Biotech, #HOOCPEG-SH) in DI water, and incubated 
overnight at room temperature, with the vials being wrapped in aluminum foil. The yield 
of the t-GNR-PEG-c conjugates could be increased with a 5 day overnight incubation, 
foil wrapping of the outer walls of the PET tubes, and inclusion of 50 mM Borate buffer 
at pH 8.6, as this environment helps to offset thiol-thiol formation. Sedimentation at 
10,000 RPM (6,800 ret) for 60 minutes, and greater than 95% decantation of the 
supernatant and resuspension into 100 mM MES buffer pH 6.1 (Sigma #M-0164) in DI 
water, helped to further increase conjugate yield. The 9 round centrifugation, and greater 
than 95% decantation, and resuspension into MES buffer pH 6.1, needed to include a 
gentle decantation-resuspension for decants 1-3. This initial gentle decantation was 
needed as residual hydrophobic groups from the CT AB hydrocarbon chains become 
exposed due to changes to its micellization. The CT AB hydrophobicity can in turn 
modulate the hydrophobic nature of the PET vial walls, causing some of the GNR to bind 
onto the wall of the container leading to a reddish film. However, the inclusion of the 
hydrophilic COOH end groups from the t-PEG-c linker and inclusion of 100 mM MES 
buffer at pH 6.1 help offset the GNR particle binding onto the walls of the container by 
promoting PET hydrophilicity. t-GNR-PEG-c conjugates were concentrated in 100 mM 
MES buffer at pH 6.1 to OD-1 0 at the LSPR peak wavelength . 
3.1.2 Antibody Bioconjugation 
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In order to perform the antibody conjugation a 5 mL aliquot of t-GNR-PEG-c 
with an OD~10 at the LSPR peak wavelength, that was stabilized by the 
heterobifunctionallinker t-PEG-c described above, was taken. The t-GNR-PEG-c were 
resuspended in 100 mM MES buffer (Sigma #M-0164) at pH of6.1 and concentrated by 
sedimentation to a volume of 100 J..lL using an absorbance of greater than 1 0 at the LSPR 
peak wavelength. A solution containing 96 mg of 1-ethyl-[3-
dimethylaminopropyl]carbodiimides (EDC, Sigma #1769), 29 mg of N-
hydroxysuccinimde (NHS, Sigma, #1306762), and 10 mL of MES buffer pH 6.1 was 
prepared, and thoroughly mixed and 10 J..lL this solution was immediately added to the 
100 J..lL t-GNR-PEG-c solution. This mixture was allowed to react for 15 minutes, at 
room temperature. Meanwhile 0.5 mL of 2-mercaptoethanol was diluted into 14.5 mL 
MES buffer pH 6.1, this being a 1 :29 ratio, then 10 J..lL of the diluted mercaptoethanol 
solution was added into the nanorod solution following the 15 minute incubation. The 
mixture was allowed to react for 10 minutes, at room temperature, after which 400 J..lL of 
antibody solution at 2 mg/mL in IX Phosphate buffered saline (PBS, Fisher 
#NC9826748) pH 7.1 was added. 
The final 500 J..lL nanorod bioconjugate solution was incubated for 2 hours at 
room temperature. The nanorod bioconjugates were separated from excess reactants and 
byproducts by sedimentation at IO,OOO RPM (6,800 ref) for IO minutes, and decantation 
of 95% of the supernatant without disturbing the pellet. The nanorod bioconjugates were 
then resuspended in 500 J..lL of IX PBS pH 7.I, and used immediately, or stored for a 
short period at 4°C. As a means to confirm the changes to the surface chemistry of the 
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antibody conjugated GNR termed t-GNR-PEG-c-Ab, LSPR absorbance and zeta 
potentional measurements were obtained. 
3.1.3 Zeta Potential 
To confirm the altered GNR surface chemistry at various stages, zeta potential 
measurements were performed using a Malvern Zetasizer Nano. Zeta potential data of 
diluted samples in water and lX PBS pH 7.1, 100 mM MES pH 6.1, and 50 mM Borate 
buffer pH 8.6, were tested using the Zetasizer Nano cuvettes (Malvern, #DTS 1 060) using 
a refractive index of 0.2 and absorption coefficient of 3.32. A control zeta of colloidal 
gold particles was obtained using similar conditions. The resulting data ranging from the 
original CTAB-GNR solution, t-GNR-PEG-c, and with the final bound conjugated 
antibody (t-GNR-PEG-c-Ab) were obtained. 
3.1.4 Fluorimetry 
Fluorimetry was used to determine the bound antibody to the GNR conjugates, 
therefore the conjugation procedure was followed with Fluorimetry using an Alexa Fluor 
488 labeled rabbit Immunoglobulin G (AF-Ab, Invitrogen, #A11059). A buffer blank, 
control antibody-buffer solution of known concentration, and sample were analyzed in a 
Horiba Jobin-Yvon FluoroLog-3 fluorimeter with CW Xenon excitation. The AF-Ab-
GNR (AF-Ab-GNR) bioconjugates were put through subsequent rounds of sedimentation 
using a 90% decant and resuspended in PBS. The free AF-Ab served as a standard curve 
to determine the concentration of the AF-Ab bound to the GNR. The calibration curve 
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was tabulated using the average number of bound peptides obtained by dividing the 
measured molar antibody concentration by the molar GNR concentration. 
3.1.5 Nanoparticle ELISA 
The GNR conjugated to mouse anti-human HER2 antibodies (NeoMarkers, #MS-
301-PABX) were incubated with horseradish peroxidase (HRP)-labeled anti-mouse 
Immunoglobulin (IgG, Sigma, #A4416) for 1 hour. Nonspecific reaction sites were 
blocked with a 3% solution of Bovine Serum Albumin (BSA). t-GNR-PEG-c-Ab were 
rinsed twice by sedimentation and resuspended in 3% BSA to remove any unbound IgG. 
The HRP bound to the conjugates were then developed with 3,3',5,5'-
tetramethylbenzidine dihydrochloride (Sigma, #T3405), and compared with HRP anti-
mouse IgG standard curve by determining the absorbance at 450 nm with a 
spectrophotometer. The resulting number of active antibodies per GNR conjugates could 
be determined and these results could be further confirmed using fluorimetry. 
3.1.6 Cell Culture & Imaging 
The t-GNR-PEG-c-Ab conjugates with anti-HER2 antibodies were then incubated 
with two cell types, these being the HER2-overexpressing epithelial breast cancer cell 
line SK-BR-3 and the normal mammary epithelial cell line MCF1 OA (American Type 
Culture Collection). The SK-BR-3 cells were grown in McCoy's SA medium 
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin and 
maintained at 37°C in a 5% C02 atmosphere. The MCF10A cells were cultured in 
Mammary Epithelial Basal Medium (MEBM) supplemented with a BulletKit (Clonetics) 
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and maintained at 37°C in 5% C02. Both cell lines were prepared for the experiment by 
putting 6 x 105 cells in chambered cover slips and allowing them 30 minutes to attach to 
the surface. The cells were rinsed once with PBS, then incubated with nanorod 
conjugates for 1 hour in 5% C02 at 37°C. The LSPR peak absorbance of the nanorod 
conjugate solution was 1.5. Post the incubation, cells were rinsed 3x with 1xPBS and 
then the appropriate cell media was added prior to imaging. The cells were imaged by 
TPL microscopy at SOX with 780 nm illumination and 400-700 nm detection.66 
KU7 cells were then grown in MEM medium supplemented with 10% FBS and 
1% penicillin-streptomycin and maintained at 3 7°C in a 5% C02 atmosphere. The cell 
line was prepared by placing 4x105 cells on cover slips and allowing them to attach to the 
surface for 24 hours. Prior to treatment, the cell media was changed to OptiMEM and the 
GNR conjugates were added for 4 hours. Post the 4 hours, the OptiMEM media was 
changed to MEM medium supplemented with 10% serum and incubated in 5% C02 at 
3 7°C atmosphere for another 20 hours. Twenty minutes prior to fixation, the cells were 
rinsed once with warm PBS, then incubated with 100 nM Alexa-488-wheat germ 
agglutinin (WGA) and left for 10 minutes in the cell incubator for WGA cellular 
internalization. After 10 minutes the cells were rinsed three times with warm PBS then 
fixed in 3.7 paraformaldehyde for 15 minutes then washed three times with cold PBS and 
mounted on slides using Slow-Fade Antifade (all reagents were purchased from 
Molecular Probes). Imaging was carried out using a Leica SP5RS AOBS confocal 
microscope using a 63x/1.4 objective. GNR were detected using 633 nm illumination in 
reflection mode, and WGA was excited at 488 nm. 
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3.2 Results and Discussion 
3.2.1 GNR Bioconjugates 
To form stable bioconjugates, a heterobifunctional PEG with thiol and carboxyl 
end groups was used, which is similar to the mPEGc5ooo)-SH stabilization discussed in 
Chapter 3. The carboxy-terminated GNR were conjugated to antibodies using the zero-
length crosslinker EDC that was stabilized by NHS.55 Standard procedures for EDC 
protein crosslinking were followed with modifications to the unique carboxyl end group 
chemistry. 56 Here the NHS and EDC groups are reacted in order to mediate the 
formation of an amide bond between amino and carboxylic groups. The highly reactive 
0-acylisourea intermediate allows nucleophilic substitution with an antibodies' primary 
amino group, thereby increasing the low efficiency of the carbodiimide-catalyzed 
reaction, this conjugation strategy is shown in Figure 3 .1. 56 
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Figure 3-1. Schematic representation of the NHS-EDC-antibody chemistry, with the 
GNR being 15 x 50 nm, and PEG chain makes a 5 nm above the GNR. 
Since the GNR do not contain amine groups, there is no aggregation Issues 
stemming from amide bond formation between the rods, this helps to minimize the 
criticality for the initial EDC exposure. To avoid buffer exchange or sedimentation 
methods, the change in pH from 6.1 to activation at 7.1 for conjugation was achieved by 
diluting the GNR into a larger volume of antibody solution. Excess reactants and 
products were then removed from the bioconjugate solution by sedimentation and LSPR 
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spectra was used to monitor changes to aggregation, this is shown in Figure 3-2. 
Antibody binding to the t-GNR-PEG-c conjugates leads to an altered refractive index, 
and dielectric constant around the surface of the nanoparticles due to the antibody layers. 
This would then cause the slightly red-shifted spectra, which serves to identify that the 
antibody has been bound to the gold nanoparticle, this is evidenced in the LSPR spectra. 70 
The t-GNR-PEG-c-Ab conjugates were then checked for antibody aggregation through 
the peak wavelength and full width height max (FWHM) of the LSPR spectra. Any t-
GNR-PEG-c-Ab aggregates were removed by pelleting-decantation-resuspension, and 
changes to the LSPR optical spectra showed their aggregation tendencies throughout the 
procedure, note that such aggregates decreased the overall product yield. 
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Figure 3-2. Spectra of the resulting GNR bioconjugates. 
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3.2.2 GNR Charge 
As particle charges are relevant for binding and aggregation purposes, the particle 
charge was measured with zeta potential, this is shown in Table 3-1. Zeta potential 
measures the effective surface potential at the hydrodynamic shear plane that is close to 
the solid-liquid interface, as this is the parameter that governs the electrokinetic behavior 
of particles in solution, which determines their electrophoretic mobility with an applied 
electric field. The ensuing electrostatic repulsion between particles is what dictates, their 
charge, and ensuing particle attraction and binding to substrates. 67 Zeta potential 
measurements confirmed that the GNR-CTAB initial charge of +83 mV was altered to-
19 m V for the carboxyl conjugated rods, to -6 m V for the antibody bound bioconjugates. 
This change is consistent with the cationic, anionic, and zwitterionic surface charges, 
associated with the three states of the bioconjugated GNR. This particle charge would be 
significant for the targeted binding of the cell since all cells contain an outermost 
negative zone composed of negatively charged glycolipid and glycoproteins which makes 
each cell act as a negatively charged body, this charge influences other nearby charged 
bodies/cells.68 In effect, a negative or slightly negative charge in the antibody conjugated 
nanoparticles would be needed for successful in vitro receptor binding, and this negative 
charge was evidenced in the zeta potential data taken from the nanorod bioconjugates. 
Table 3-1. 
Nanoparticle 
NR-CTAB 
NR-S-PEG-COOH 
NR-S-PEG-Ab 
Zeta Potential (mY) 
+83 
-19 
-6 
Zeta potential measurements confirm surface chemistry modification. 
37 
3.2.3 GNR Bioconjugate Fluorimetry 
To characterize the final bioconjugates, the t-GNR-PEG-c were conjugated to AF-
Ab for fluorimetric analysis. The GNR bioconjugates were put through successive 
rounds of sedimentation, 90% decantation and resuspension in buffer to dilute the 
unbound AF-Ab by factors of 10. Fluorimetry of unbound AF-Ab in the decants is 
shown in Figure 3-3, and served to make the standard titration curve. Background 
fluorescence noise was evident by the 4 th round, which is when the AF-Ab concentration 
is at 0.1 nM. Fluorimetry of the t-GNR-PEG-c-Ab bioconjugates indicated that the 
nanorod bound AF -Ab concentration was 1 nM, this yields approximately two antibodies 
per GNR, given a concentration of 0.5 nM from the LSPR extinction peak. 73 
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Figure 3-3. Fluorimetric analysis of GNR conjugates. The dashed curves display the 
signal from free labeled antibodies in solution at the stated concentrations. The solid 
curve displays the signal from nanorod conjugates. 
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3.2.4 Antibody Conjugation Yield 
An ELISA antibody test was performed in order to tabulate the number of active 
antibodies per t-PEG-c-GNR-Ab bioconjugates. 84 The Nanoparticle ELISA method 
used, is similar to the traditional ELISA except that the immunosorbent surface is that of 
the nanoparticles in solution. The nanoparticle ELISA indicated that there were 2.28 +/-
0.05 antibodies per nanorod, which agrees with the fluorimetry results. A control ELISA 
of GNR prepared with mPEG-SH and no capture antibodies yielded 0.68 +/- 0.2 
antibodies per nanorod. This latter result possibly stemmed from an artifact due to the 
label antibody chemisorbing to the GNR surface or antibody adsorption, however the 
control targeting showed to be insignificant. 
3.2.5 Nanorod Targeting 
The resulting GNR bioconjugation scheme was tested in vitro using two cancer 
cell lines and respective cancer antibodies. t-GNR-PEG-c were conjugated to Anti-HER2 
and also to rabbit lgG as a control. Each GNR bioconjugate was incubated with the 
HER2-overexpressing epithelial breast cancer cell line SK-BR-3 and the normal 
mammary epithelial cell line MCF10A (American Type Culture Collection) for 30 
minutes under identical conditions. The respective cells were washed and immediately 
imaged using TPL, which highlighted the presence of the GNR, as well as phase contrast 
which evidenced the respective cell locations, this is shown in Figure 3-4. The TPL was 
conducted at 0.1 mW, 780 nm illumination with detection at 400-700 nm, using a SOX 
objective, with a scanning area of 60 fJ.m x 60 fJ.m, and a total irradiation time of 1.05 
seconds per scan. The TPL image showed the resulting GNR-anti-HER2 targeting 
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results, with red being indicative of a significant level of GNR binding to cells that only 
occurred for the specific antibody-cancer cell combination. Figure 3-5 shows dark-field 
images of targeted GNR and control cells from the same sample, and evidenced that the 
GNR were not visible. To test the antibody targeted t-GNR-PEG-c-Ab conjugate 
visibility under dark field microscopy, isolated GNR were deposited on glass substrates 
near alignment marks and compared to easily visible spherical gold nanoparticles, this is 
shown in Figure 3-6. Here images of a single GNR and single gold nanosphere were 
taken under dark field microscopy using a high sensitivity black and color charge-
coupled device (CCD) cameras, and AFM imaging which was performed on the same 
area. The GNR was not detectable using either the high-sensitivity monochromatic or 
color CCD cameras. In vitro GNR imaging of GNR bioconjugates of C225 and human 
IgG control were tested in the KU7 bladder cancer cell line by confocal reflectance, this 
is shown in Figure 3-7. The t-GNR-PEG-c-Ab bioconjugates were imaged by confocal 
reflectance at 633 nm. The cells were visualized with a WGA fluorescence label, 
yielding the cell location in green, and bound GNR by confocal reflectance in red. t-
GNR-PEG-c-Ab bioconjugate binding is only observed for the specific C225 conjugates 
and the KU7 cells and not the control lgG, as noted in Figure 3-7. 
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CF10a 
Figure 3-4. GNR conjugate targeting. Phase contrast shows the cell locations in 
grayscale, and TPL is displayed in red. Binding was only observed for the Anti-HER2 
conjugates and SKBR3 cells. 
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Anti-HER2 lgG 
SKBR3 
Figure 3-5. 
Figure 3-6. Dark field microscopy images of a single GNR on glass. The first AFM 
image (A) shows a region near alignment marks that are also visible in the optical images 
(C and D). A zoomed AFM image (B) reveals a large nanosphere in the upper right 
(triangular shape is a tip artifact) and a nanorod in the lower left. The GNR is clearly 
revealed in the inset. Its size is exaggerated by the tip. The true size is approximately 50 
nm length and 15 nm width. Dark field images captured with a high sensitivity CCD (C) 
and color CCD (D) clearly show the nanosphere, but show no sign of the nanorod in the 
expected region, even with significant contrast enhancement. The inset boxes in A, C, 
and D are all shown at the same size and position. 
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GNR C225 
Figure 3-7. In vitro nanorod imaging by confocal reflectance. WGA fluorescence 
shows the cell location in green, and confocal reflectance at 633 nm illustrates nanorod 
binding in red. Nanorod binding is only observed for the specific C225 conjugates and 
KU7 cells. 
3.2.6 Conjugation Discussion 
To date in vitro and in vivo GNR targeting experiments have been mostly carried 
out with CT AB-capped gold GNR stabilized with polyelectrolytes, followed by the 
. . d 1 b" d" f "b d" h . 35-36 38-40 42-43 mtxtng an non-cova ent tn tng o anti o tes or ot er targeting agents. ' ' 
These strategies compare to the antibody bound citrate-capped gold nanoparticles that are 
often used for immunoelectron microscopy where the binding often results from weak 
electrostatic and hydrophobic interactions.85-86 The t-GNR-PEG-c functionalization 
described in this work makes use of an amide bond between the linker and antibody, and 
a strong gold-thiol bond between the thiol linker and the GNR. Amide bond formation 
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with antibodies has likewise been explored with various methods which included, 
polyelectrolytes that housed exposed carboxyl groups, or with alkanethiols that contained 
bifunctional PEG linkers.37'44'87 This latter method often remains problematic due to the 
low aqueous solubility of alkanethiols, which makes it necessary to employ elevated 
temperature and sonication to achieve the concentrations needed to displace CT AB. 87 In 
vivo applications can benefit from more optimized gold-thiol and covalent bond 
conjugations that are application tailored, however the bioconjugation described here is 
reproducible for cancer cell targeting in spite of the strong CT AB-gold interaction. 35 
Zeta potential testing showed that changes to the intended surface chemistry were altered 
for the negatively charged t-GNR-PEG-c, near neutral for the zwitterionic antibody t-
GNR-PEG-c-Ab bioconjugates, and positive for the original CTAB-GNR. Fluorimetric 
assays confirmed that there were two antibodies per GNR, and Nanoparticle-ELISA 
suggested that a large fraction of these antibodies were active. Successful in vitro cell 
targeting was then shown with two cell types and different antibodies. 
3.2. 7 Microscopy & Scattering Characterization 
Sensitive characterization techniques, allow for the detection and spectroscopies 
of individual nanoparticles, however the optical detection of single nanoparticles remains 
a challenge.12 In order to overcome this, total internal reflection, and Rayleigh intensity 
scattering have been used, as these are able to detect particles above 40 nm.12 Such 
methods have been unsuccessful in smaller sized particles as it is difficult to differentiate 
the scattered intensity of nanoparticles from the background of fellow scatterers. 12'71 
Under confocal microscopy the nanoparticles can function as optical contrast agents that 
increase the visibility of the cells under reflectance mode imaging. 12'71 Since the targeted 
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t-GNR-PEG-c-Ab bioconjugates are able to bind to cancer cells, they can produce 
reflective signals that function as biomarkers that can discriminate between cancer and 
normal cells. The strong resonant light scattering response of gold nanoparticles is 
enhanced when the gold nanoparticles cluster around the cell membrane, as their surface 
plasmons are able to interact with each other upon excitation by light. 12'71 Once this 
dipole oscillation is induced it produces the scattering of particles, and oscillations that 
are of the same polarization as the incident light beam. 12 The oscillating dipoles will then 
reradiate the light with the same polarization, and the intensity of the scattered light from 
the particles will be asymmetric about the GNR. The laser-nanoparticle interaction, then 
produces strain waves and surface polarization currents that cause the scattered 
electromagnetic energy to re-radiate from the particles, leading to the ultimate signal that 
the observer sees. 12 Photothermal methods which also rely on the absorption properties 
of the GNR, which vary with the third power of the particle size, also present an 
advantage to highly scattering environments, and finds applicability in absorption 
spectroscopy and live cell imaging studies.71 The photothermal effect arises from the 
excitation of the surface plasmon resonance of the metal nanoparticles, which have a 
large absorption cross-section, and exhibits a fast electron-phonon relaxation time, which 
makes them very efficient light absorbers. Since the luminescent yield is quite weak, 
almost all the absorbed energy is converted into heat, leading to increased temperatures 
that cause variations in the refractive index of the absorbing particle. 12 
3.2.8 Conjugate Imaging Discussion 
Different imaging methods were used to visualize the bioconjugates in and around 
cells. TPL images shown in Figure 3-4 clearly reveal the GNR in the samples. What was 
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also evidenced in the figure is the nonspecific binding of the antibody to a bare plastic 
surface which had not been substrate modified. This often occurs due to a hydrophobic 
substrate-protein interaction due to the water molecules on the plastic substrate having a 
much higher affinities for each other. This exclusion of hydrophobic sites in the aqueous 
solution can lead to parts of proteins being adsorbed onto the hydrophobic parts of the 
plastic substrate. The nonspecific binding of the antibody to the hydrophobic portions of 
the plastic substrate, which is noted in red, is the background signal noted in Figure 3-4. 
Note that this behavior was also seen in the PET vials used for the initial t-GNR-PEG-c 
conjugation. 
Dark field microscopy results, which are shown in Figure 3-5, was also used to 
detect the GNR in cells, as this technique is likewise able to pick up the striking 
modalities of the plasmon resonant nanoparticles. 88 The complication of dark field 
microscopy is that the optical scattering needed to provide the dark field constant is a 
strong function of the nanoparticle size. An additional issue stems from the size range at 
which the nanoparticles become visible by dark-field methods, which is tens of 
nanometers, and which is similar to the range of nanoparticles that have been used in 
biomedical applications. Visibility issues are also sensitive to the illumination, imaging 
numerical apertures, spectral range, nanoparticle aggregation, and background scattering 
from the cells. This poses a complication for dark field, as the strong background 
scattering of the cells complicates the scattering stemming from the cross-section of the 
GNR. This makes it necessary to cautiously analyze the targeting of the t-GNR-PEG-c-
Ab bioconjugates by dark-field methods. Dark-field images in Figure 3-5 reveal no 
evidence of scattering the t-GNR-PEG-c-Ab bioconjugates, while TPL imaging in Figure 
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3-4 clearly shows the presence of the GNR. This suggests that the 15 x 50 run GNR do 
not scatter sufficiently to be visible against the background scattering of the cells. This 
means that the dark field samples are unable to distinguish the t-GNR-PEG-c-Ab 
bioconjugates when compared to the cell scattering, this is further confirmed by the dark 
field images taken from the single GNR glass substrate sample as shown in Figure 3-6. 
While AFM and alignment marks were used to confirm the location of the single GNR 
relative to the larger spherical particle, the dark field images failed to confirm the rod 
with either a color CCD camera or back-illuminated electron multiplying CCD camera. 
This is indicative that visibility is lacking in both the cell and glass substrate samples. 
Other methods could be used to increase the GNR imaging signals, and contrast 
such as spectrally filtering the scattered light, exciting with monochromatic illumination 
at the plasmon resonant wavelength, and using higher numerical aperture condensers and 
objectives can be implemented. However, confocal reflectance microscopy coupled with 
monochromatic illumination at the LSPR wavelength and reduced background signal, 
was sufficient to detect the targeted GNR in the KU7 cells, this is shown in Figure 3-7. 
It would seem that the contrast levels between the TPL and confocal reflectance in the 
cell samples may be relevant. TPL however was enough to detect individual or a small 
cluster of GNR that were undetected in dark field microscopy, this is shown in Figure 3-
4, this is expected as other groups have shown the use of TPL for GNR imaging. 66 This 
suggests that dark field methods would require spectral filtering of the scattered light, 
excitation with monochromatic light at the plasmon resonant wavelength, and/or use of 
higher numerical apertures, and condensers and objectives in order to increase the GNR 
imaging signals. However, GNR that are significantly aggregated due to high-density 
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binding, may become visible in dark field measurements. These results indicate that the 
targeted GNR can be visualized below the aggregated level using monochromatic 
illumination at the LSPR wavelength, with reduction in background noise. 
3.3 Conclusion 
GNR targeting experiments were successfully carried out with stable 
bioconjugates that resulted from the use ofNHS-EDC chemistry and a bifunctional PEG 
with thiol and carboxyl end groups. This resulted in the formation of an amide bond 
between the linker and antibody, and the strong-gold thiol bond between the linker and 
GNR. The carbodiimide linking strategy was successful in producing carboxy-terminal 
PEGylated GNR that could undergo successful bioconjugation with antibodies. 
Furthermore this conjugation strategy was reproducible despite the strength of the 
original gold-CTAB interaction. Zeta potential measurements were able to confirm 
changes to the intended surface chemistry, leading to negative potentials for the carboxy-
terminated GNR conjugates and near-neutral charge for the zwitterionic antibody protein 
GNR bioconjugates. Fluorimetric assays suggested that two antibodies per nanorod were 
present and Nanoparticle ELISA assay demonstrated that a large fraction of these bound 
antibodies were active. Successful in vitro targeting of the GNR bioconjugates were 
shown in two cell types using the HER-2 and C225 antibodies. TPL and confocal 
reflectance were then used to successfully image the t-GNR-PEG-c-Ab particles that 
were successfully internalized by the cells. 
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CHAPTER4 
NIR Plasmonic Gene Therapy Vector 
Genetic diseases are unfortunate worldwide threats in human society that occur as 
a result of mutations in the DNA sequence of healthy cells. Gene therapy has the 
promising potential to create safe and effective treatments for genetic diseases ranging 
from inherited disorders and incurable cancers to viral infections. In gene therapy, the 
successful delivery and integration of genetic material such as DNA or RNA, can modify 
the encoding of the target proteins, and may restore their function as well as expression 
level to a disease-free state.90 Yet, in order to successfully achieve a therapeutic effect, 
several methods and conditions have to be met, these include: (i) to synthesize a DNA or 
RNA sequence that contains the protein coding information; (ii) to deliver this safely 
inside the cell using a designed optimal vector; (iii) to design a system that caters to 
receptor mediated endocytosis in order to avoid the reticuloendothelial system (RES) 
clearance and macrophages, and (vi) to escape the endosomes and gain access to the 
cytoplasm and associated nuclear membrane without degradation.90"91 Then in order to 
affect gene expression, the relatively short sequences of genetic material must be 
complementary to mRNA. Once this complementary match is achieved, then blocking of 
the translational initiation, or mRNA processing, and the subsequent destruction of the 
mRNA can occur. 
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4.1 Gene Therapy Introduction 
4.1.1 Gene Therapeutics 
Gene-, stem cell/protein-, and nano-based therapies are now becoming new 
approaches in molecular medicine, and this stems from their increased ability to deliver 
therapeutic drugs and genetic material to the target cells. Gene delivery therapies still 
present a variety of potential problems, and this may be due to the fact that 
oligonucleotides such as DNA, and RNA, are often unstable in an environment with high 
ionic strength such as blood, where charges from electrolytes and salts may lead to 
aggregation.90"91 The short half-life of naked genetic material (less than five minutes in 
plasma) and its degradation and clearance following systemic injection, makes it is 
necessary to use a suitable delivery system, such as vectors.90-91 Several delivery vectors, 
which are viral or nonviral in nature, have been developed to facilitate the transfer of 
genetic information into a cell. Determining the size of the genetic material being 
transferred, identifying the target cells and their optimal ability to be transfected, and 
subsequent longevity of expression, may also help address some of these issues.90-93 
4.1.2 Delivery 
A major hurdle in gene therapy, is the difficulty in being able to efficiently 
transfer a highly negatively charged DNA, RNA molecule or other genetic material into a 
cell using either ex vivo or in vivo delivery methods.90-93 For ex vivo delivery, 
DNA/RNA can be transferred into cells using calcium-phosphate precipitation, 
electroporation, cationic or anionic lipids, liposomes, dendrimers, polymers, or 
nanoparticles.90-92 The transfected cells can then be selected by virtue of a selectable 
marker that is recognized by the DNA, RNA, or oligonucleotide. Some genetic material 
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requires the use of a combination of delivery vehicles such as liposomes, cationic or 
anionic lipids, polymers, and nanoparticles in order to increase the low transfer 
ffi . 90-94pl b ~. . 1 "1 . d e 1c1ency. asma mem rane 1USion protems, po ymer, or nanopart1c e-ass1ste 
delivery systems that wrap or shield the genetic material have also been employed.94 Yet 
changes to the chemical composition of the delivery vectors must be optimal in order to 
ensure that they are physiologically compatible and successfully internalized often by 
exploiting receptor-mediated endocytosis targeting strategies into endosomal 
compartments. The nuclear delivery and binding of the DNA/RNA material will then 
tum genes on or off, by adding, replacing, or correcting the diseased genes. This allows 
the endogenous target mRNA to be modified in order to alter its transcription, which 
leads to a therapeutic effect. While viral and nonviral vectors differ in terms of their 
overall efficiency the latter specifically lag behind viruses in terms of transfection 
ability. 90-94 Existing technologies currently exploit the binding and condensing of nucleic 
acids, subsequent vector unpackaging, endocytic escape, and cytoplasmic mobility. 
Novel emerging technologies are being developed to fine tune the protection of the 
nucleic acid cargo material, its endosomal delivery and escape, and nuclear localization.94 
Appropriate formulation conditions are still being investigated in order to avoid toxicity 
Issues. 
4.1.3 Gene Delivery vectors 
To increase the efficiency of gene therapy by non-viral means, plasmid DNA 
vectors can be complexed by physico-chemical methods to either polymeric, lipid, and/or 
plasmonic vectors.90-100 Plasmid vectors are small circular molecules of double stranded 
DNA that are naturally derived from plasmids found in bacteria. Plasmids are 
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transferrable genetic elements of DNA that are capable of autonomous replication within 
a suitable host. Being able to function similar to viruses, plasmids can transfer genetic 
information non-genomically, however their lack of a protein coat hinders their ability to 
move from cell to cell, thereby restricting movement within a single cell. Plasmid 
vectors have three main components, these being an origin of replication which facilitates 
extraction and allows for replication inside the host cell, an encoded antibiotic resistance 
gene that is selective to growth, and polylinker DNA sequence that contains enzyme 
restriction sites that allows for the insertion of mammalian DNA/RNA sequence of 
interest.93-100 Plasmid vectors help to facilitate the nuclear delivery and subsequent 
protein expression of the gene of interest. Except during mitosis, which is when the 
nuclear envelope breaks down, the only way molecules can enter the nucleus is by taking 
advantage of the nuclear pore complex which allows for the passive diffusion or active 
transport of molecules. Plasmid vectors are able to·enhance the transfectability of mitotic 
cells whose nuclear envelope breaks down during reproduction.93-100 Yet the diffusional 
barrier of the nuclear envelope continues to pose a problem to the cytoplasmic stability of 
plasmid DNA, resulting in their low nuclear delivery and gene transfer abilities. 
Among all the various gene carriers, viral vectors are the most widely investigated 
to date because of their efficient transformation efficiency.90-94 Lentiviral, adeno-
associated virus, and other retroviral vectors have been extensively researched for stable 
expression of short hairpin RNA due to viral vectors ability to successfully insert into the 
host genome.95'90-94 However, due to viral re-activation, gene control, and 
immunogenicity, safety issues are still problematic for benchside medical and human 
trials. Molecular encapsulation by liposomes, polymers, and dendrimers has also been 
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used, but these are less efficient than viral vectors and can suffer from increased 
toxicity.90-100 Plasmonic nanostructure based vectors are now being actively researched 
due to their low immunogenicity, non-toxicity, and compatibility.92•99"100 In addition 
these vectors are more effective at achieving gene delivery and can be engineered for 
d 1 1 . d' . 100 controlle re ease upon aser ura 1at1on. 
4.1.4 Viral vectors 
The viral gene therapy approach uses replication defective viruses where part or 
all of the viral coding sequence is replaced by therapeutic genetic material. Viral vectors 
confer highly efficient delivery as they avoid plasma components by using their capsid 
proteins to attach to cells, which often significantly reduce and/or lead to the elimination 
of transfection agents. Types of viral vectors include retroviruses, which are a type of 
lentivirus that uses a reverse transcriptase to transcribe RNA to DNA. 90"95 Retrovirus 
vectors can achieve a long-term expression in cycling cells, resulting in high viral titers 
that can enable the transduction of non-dividing cells.90-95 A drawback of the use of 
retroviruses rests in the integration of the viral genome into the host genome, which is a 
random process that carries a high risk of insertional mutagenesis. Other vectors such as 
the Adenovirus-based vectors, use an icosahedral virus with a large DNA genome that 
can infect dividing and non-dividing cells, leading to high viral titers. Adenovirus based 
vectors will transduce a wide range of target cells leading to high-level gene expression. 
However, since they are non-integrating vectors their expression in dividing cells is 
progressively lost. Adenoviral vectors are suitable for applications that require a 
transient, high level activity, and where immune responses to the vector and transgene 
expression are acceptable. Toxicity associated with the repeated administration of 
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vector type that often uses a small nonpathogenic DNA virus that can only produce 
progenies in the presence of helper viruses. In the absence of helper virus, it incorporates 
a genome into the chromosome of host cells.90-95 Adeno-associated virus vectors can 
yield high viral titers and transfect both dividing and non-dividing cells. However, their 
application is limited by toxicity and packaging size constraints. 
While viral vectors are great for in vitro gene therapy, problems arise with non-
replicating cells, and in vivo studies. The infectivity and compatibility match up of viral-
cell types often restricts their use, while packaging and size limitations hinders associated 
insertional sequences. Viral self-replicating capabilities with unique recombination and 
complement activation are also problematic, as is the inability to bypass the host's 
defense mechanisms.90-95 Insufficient pharmaceutical quantities, termed viral titers, and 
the limitation of the amount of genomic information that can be introduced into these 
vectors are also complications. 90-95 
4.1.5 Nonviral vectors 
The aforementioned problems associated with the use of viral vectors have led to 
the development of a nonviral approach to gene therapy, which abstains from the use of 
any viral particle but uses instead a combination of plasmid vectors, polymers, cations, 
anions, nanoparticles, lipids, and oligonucleotides, which work together to emulate viral 
gene delivery vectors.90-100 RNA, DNA, or other genetic material that can undergo 
amplification in bacteria and cells, and/or which can be chemically synthesized can be 
used. Nonviral vectors differ from each other only in their self-assembly which is 
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controlled by the order of addition of components, subsequent charge, and resulting 
polydispersity. 
Types of nonviral vectors include naked or free DNA, which is often given as an 
intratumoral injection.94 While naked DNA can induce a transgene expression that is 
high enough to confer a therapeutic response, its systemic administration needs to be 
protected from endonuclease degradation. More efficient DNA transfer can result from 
the use of ballistic DNA injection which use micron sized gold particles that are coated 
with a plasmid DNA that encodes the gene of interest.94 The plasmid coated gold 
particles are then placed onto a carrier sheet that is housed in a discharge chamber, which 
can be accelerated by a motive force to penetrate cell membranes. Lipoplexes are 
another type of nonviral vector that are often used for cancer-based studies. The lipoplex 
uses lipid-encapsulated plasmid DNA creating an organized and complexed structure 
resembling that of a micelle or liposome.96 Lipids, which can be anionic, cationic, or 
neutral, can then complex to DNA through a charge interaction. Often helper lipids are 
included in the formulation because they can increase the intracellular trafficking of the 
genetic material. 96 Helper lipids have been shown to fuse with the endosomal membrane 
to deliver the internalized cargo molecules, and facilitate their diffusion into the 
cytoplasm. For example, a helper lipid such as polylysine, uses weak intermolecular 
forces that arise from interactions between charges and dipoles, and hydrogen-bonding 
(H -bonding) between amino and phosphate groups, to create particles that are small 
enough to enter cells. 96 By virtue of their ability to exploit weak intermolecular forces 
such as ionic, H-bonding, hydrophobic, and solvent exclusion, lipoplexes can also 
produce a tight condensation of the DNA into a heterochromatin structure, which further 
55 
favors delivery. Another nonviral gene delivery vehicle is a polyplex, which is a 
polymer-DNA complex that often consists of positive cationic polymers, complexed with 
anionic DNA. DNA interactions with cationic polymers and liposomes occur through 
charges that help to compact the DNA/RNA molecules and promote binding. To date, 
lipoplexes and polyplexes are the most successful non-viral gene delivery vehicles.96 
Given the immune system's lack of exposure to non-viral vectors, there is little 
chance of patients having high titers of neutralizing antibodies against them.93"94 
Furthermore, their size can compare to viral vectors, which makes them small enough for 
endocytosis. The non-immunogenicity, low acute toxicity, and simplicity of non-viral 
vectors makes them attractive candidates for gene delivery. Yet the inefficient delivery 
of non-viral vectors can result from size and charge constraints, which can lead to 
overwhelming van der Waals forces in the particles resulting in aggregation.93 Major 
delivery barriers/obstacles include transfection, which can be influenced by the 
interactions between the colloidal and surface properties of the delivery vector, and the 
compacted or condensed nucleic acid cargo material.93"94 A variety of strategies have 
been developed to improve the efficiency of non-viral vectors, for instance through 
enhanced cellular internalization by receptor mediated endocytosis, the endosomal escape 
and nuclear localization of the genetic material is encouraged. 93"94•96"102 Drawbacks of 
non-viral vectors include their large-scale production, lower efficiency in gene transfer, 
and transient gene expression. Formulation barriers, batch-to-batch variability, and 
issues with synthetic material synthesis, and purification are also still plaguing.93 
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4.1.6 Colloidal Gene Vectors 
Less expensive synthetic delivery vectors such as charged colloidal gene therapy 
vehicles with excess positive or negative charge have also been researched.94 A 
drawback with colloidal systems is that they often fail to reach the target cells due to 
interactions with the extracellular matrix (ECM) proteins and cell surface lipids. Current 
research has shown that nanotechnology based, plasmonic-vectors that are non-viral in 
nature can be used for gene delivery.99-100 Plasmonic nanoparticle-based vectors have 
already been used to successfully deliver genetic materials into cells, and in some cases 
are helpful in overcoming the packaging size constraints that plague the established viral 
and non-viral vectors. 103-109 Nanotechnology-based approaches have also shown to have 
minimal toxicity or side effects both in cell culture and animal models. 99-100,103•109 
4.1. 7 Gold Nanoparticle based therapies 
GNR are 20 nm in diameter and 80-nm long, solid-gold cylinders and exhibit 
tunable NIR extinction that allows for their extensive use m cancer 
therapeutics/diagnostics, photo-thermal cancer therapies, and in diagnostic molecular 
imaging_uo-m While bulk gold has been deemed safe, the biocompatibility and 
environmental risks of nanoscale gold particles need to be clarified prior to their large 
scale manufacturing for in vivo use. 112•113 The non-toxic nature of the GNR comes to 
light after the cytotoxic dispersants (CTAB) have been replaced by biopolymers. It has 
been shown that a three-day in-vitro exposure of K562 leukemia cells to 100 nM 
concentrations of nanoparticles was in fact nontoxic. 114 However, free CTAB has the 
potential to lyse cell membranes and cause nonspecific binding interactions that are 
detrimental to gene therapies. 114 Therefore a key step for in vivo work is the removal of 
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CT AB combined with an appropriate nanorod purification step. The cytotoxicity of GNR 
can also be reduced by overcoating them with PEG polymers, which helps reduce 
nonspecific binding of biological molecules to cell surfaces in general. 115-116 GNR coated 
with CTAB and subsequently overcoated with polyelectrolytes show 90% viability for 
HeLa cells and cause little change in the levels of gene expression: only 35 out of 10,000 
genes were mildly down-regulated. 116 However, polyelectrolyte stabilization of GNR can 
suffer from instabilities at certain pH values and ionic strengths. Although standard 
assays of polymer functionalized nanoparticles do not evidence cytotoxicity, they may 
still cause serious cellular damage, such as an increase in actin filaments and decrease in 
cell proliferation and adhesion. 117 Cytotoxicity may also depend on the cell type used and 
the type of material used to construct the nanoparticles. 118 
4.2 RNA therapeutics 
4.2.1 RNA Silencing 
RNA based therapies such as silencing RNA (siRNA), are now highly sought 
after for non-actively dividing cells.96•102 The post-transcriptional gene silencing by RNA 
interference is known as RNAi, was first observed in plants, and is a mechanism that can 
be exploited by cells to conduct gene regulation and as a strategy of defense against 
foreign (viral) RNA.96•102 siRNA gene therapies work by silencing target mRNA by 
binding complementarily to small RNA molecules, which takes advantage of the extreme 
specificity of Watson-Crick base pairing. siRNA molecules contain a catalytic 
component that enables a single siRNA molecule to silence or destroy thousands of 
copies of mRNA molecules. When compared to regular anti-sense technology where 
nucleic acid molecules can bind to and silence only a single mRNA molecule, siRNA 
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silencing is extremely efficient. In mammalian cell lines, siRNA is generated by a 
cleavage of larger double stranded RNA ( dsRNA) precursors through the RNAse II 
endonuclease dicer. 96•102•119 Dicer forms a complex with the TAR-RNA binding protein 
(TRBP) which hands siRNA to the RNA-induced silencing complex (RISC), which 
contains the protein that conducts the silencing activity by cleaving the target mRNA 
molecule between bases at the 5' end of the antisense siRNA. The core of RISC 
contains Ago-2 (a member of the Argonaute protein family), which carries out the 
catalytic cleavage activity and releases the passenger strand, leading to an activated form 
ofRISC with single stranded RNA (ssRNA). 96•102•119 mRNA with perfect or near perfect 
complementarity to the guide RNA is then used by Ago-2 to recognize and cleave the 
target. Partial complementarity to siRNA and target mRNA, represses translation and 
destabilizes transcripts if the binding mimics micro RNA (miRNA) interactions with 
target sites. The miRNA is the endogenous substrate for the RNAi machinery and is 
expressed as a long primary transcript (pre-miRNA). This pre-miRNA is then processed 
within the nucleus into a 60-70 base pair (bp) hairpin by a microprocessor complex. 
Further processing in the cytoplasm by the RNAse III dicer complex removes the hairpin 
loop of the pre-miRNA. Only one of the two strands of the pre-miRNA is then loaded 
into the cytoplasmic RISC complex. Partial complementarity of the miRNA with the 
sequences 3' untranslated region (UTR) of the target mRNA allows for the translation 
repression and associated message degradation. 96•102•119 It becomes possible to exploit 
this native gene-silencing pathway for the regulation of genes, if a siRNA effector 
molecule with one strand of complementarity matches that of the target nucleotide 
sequence. 96•102•119 This complex can then be delivered into a cell to activate RISC 
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directly, resulting in specific silencing of the target mRNA. This is often the method of 
choice for silencing and controlling disease-associated cancer genes in mammalian cell 
lines. 96•102•119 However, the cytoplasmic delivery of such molecules is still very 
problematic, making it necessary to use gene delivery systems in order to prolong the 
genetic materials cytoplasmic stability. 
4.2.2 Bladder Cancer Therapeutics 
Urothelial carcinoma of the bladder (UC) is a significant health threat to the U.S. 
population, and the integrated clinical and laboratory investigations of this disease have 
lagged behind those of other forms of cancer. 120"122 Rapid advances in our understanding 
of cancer biology have not been translated into improved patient care, and there have 
been no major advances in therapy for this disease since Methotrexate-Vinblastine-
Adriamycin-Cisplatin (M-V AC) chemotherapy was introduced over 20 years ago. 120"122 
Despite the obvious need to make the most of the available cytotoxic drugs, there is an 
undeniable reality that such efforts are unlikely to provide a quantum leap in survival. 
There is a pressing need to expand the paradigm as many of the newer biologic cancer 
therapeutic agents such as growth factor antagonists, tyrosine kinase inhibitors, and anti-
angiogenic agents have yet to be fully utilized in urothelial cancers. There are also many 
potential therapeutic targets for gene transfer strategies that are relevant to the 
pathogenesis of bladder cancer. For example, some studies have shown that some growth 
factors, such as Heparin Binding-EGF (HB-EGF), Basic Fibroblast Growth Factor 
(bFGF), and Cripto which are often found in highly malignant cancers are of interest in 
bladder cancer based gene therapies. 123 Although the biologic activity of the nuclear-
localized growth factors is not fully understood, it appears that by targeting the 
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expression of these ligands through siRNA, one could efficiently block their nuclear 
function. 123 
4.2.3 siRNA-GNR Plasmonic Vector 
In this investigation we studied untreatable forms of bladder cancer with antibody 
targeted thiol-PEG-carboxyl functionalized GNR that trapped a glyceraldehyde-3-
phosphate (GAPDH), Fluorescein isothiocyanate (FITC) labeled siRNA, termed 
GAPDH-siRNA-FITC that was housed within a Luciferase based plasmid vector. The 
targeted thiol-PEG-carboxyl-GNR (t-PEG-c-GNR) conjugates were covalently bonded to 
the EGFR/C225 antibody, in order to enhance C225-induced EGFR receptor-based 
endocytosis. Receptor-mediated targeting was used to deliver the kinetically trapped 
GAPDH-siRNA-FITC that was housed within the PEG layer. Heating methods were 
used to trap and release the GAPDH-siRNA-FITC from the PEG, based on activation of 
the polymer pour point and salt based electrostatic screening of the PEG-COOH groups. 
The advantage of this strategy is that it allows for the preferential delivery of the 
GAPDH-siRNA-FITC into tissues and cell types that differentially express the EGFR 
receptor, and facilitates delivery into the appropriate endosomal compartment. 120 The 
down regulation of the GAPDH gene was targeted by the siRNA as GAPDH has been 
shown to be up-regulated in many cancers and down-regulated by chemotherapeutic 
drugs. 124 Changes to the GAPDH mRNA expression are therefore highly relevant to 
cancer-based gene therapies. Cell culture, and subsequent imaging by TEM, TPL and 
confocal microscopy were used to view the internalized conjugates, while RT-PCR 
determined if the release of the GAPDH-siRNA-FITC caused a reduction in the 
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expression of GAPDH mRNA. Plasmonic gene silencing of the gene by the GAPDH-
siRNA-FITC will be compared to the lipid based Dharmafect control in terms of 
transfection ability. GAPDH was chosen as the protein target of the siRNA since its 
expression is highly correlated with cell proliferation, increased metastasis, and tumor 
aggressiveness, where any decrease in overexpression correlates with inhibition of cancer 
cell proliferation, invasive tumor growth, and decreased metastatic potential. 
4.3 Methods 
4.3.1 GNR Bioconjugates 
A 5 mL aliquot of GNR with an OD~ 10 at the LSPR peak wavelength which was 
stabilized by the t-PEG-c-GNR conjugation protocol described in Chapter 3. The GNR 
were resuspended in 100 mM MES buffer at pH of 6.1 and concentrated by 
sedimentation to a volume of 100 f..I.L using an absorbance of greater than 1 0 at the LSPR 
peak wavelength, and filtered using a low-protein binding filter (0.22 f.l pore size). A 
solution containing 96 mg ofEDC, 29 mg ofNHS, and 10 mL ofMES buffer pH 6.1 was 
filtered using a low protein binding filter (0.22 f.l pore size) and 10 f..I.L of this solution 
was immediately added to the 100 f..I.L nanorod solution. This mixture was allowed to 
react for 15 minutes at room temperature. Meanwhile 0.5 mL of 2-mercaptoethanol was 
diluted into 14.5 mL MES buffer pH 6.1 (1:29 ratio), and filtered using the low protein 
binding filter (0.22 f.l pore size), and 10 f..I.L of the diluted mercaptoethanol solution was 
added into the nanorod solution following the 15-minute incubation. The mixture was 
allowed to react for 1 0 minutes at room temperature, after which 400 f..I.L of filtered 
antibody solution at 2 mg/mL in Phosphate buffered saline (PBS), pH 7.1, was added. 
The final 500 mL nanorod bioconjugate solution was incubated for 2 hours at room 
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temperature. The nanorod bioconjugates were separated from excess reactants and 
byproducts by sedimentation at 10,000 RPM (6,800 ref) for 10 minutes, which lead to a 
pellet that underwent a 95% decantation. The pelleted GNR bioconjugates were then 
resuspended in appropriate buffers. 
4.3.2 Zeta Potential 
As a means to confirm the changes to the surface chemistry of the conjugated 
GNR, LSPR absorbance spectra and zeta potential measurements were performed using a 
Malvern Zetasizer Nano at various stages of GNR conjugation ranging from the original 
CTAB solution, t-GNR-PEG-c, and the final t-GNR-PEG-c-Ab. Zeta potential data of 
diluted samples in water and 1X PBS pH 7.1, 100 mM MES pH 6.1, and 50 mM Borate 
buffer pH 8.6, were tested in Zetasizer Nano cuvettes using a refractive index of 0.2 and 
absorption coefficient of 3.32. A control zeta of colloidal gold particles was obtained 
using similar conditions. The resulting data ranging from the original CT AB solution, 
and the final t-GNR-PEG-c-Ab were obtained. 
4.3.3 Cell Lines and culture conditions 
The SK-BR-3 breast cancer cells were obtained from Dr. Liana Adam's 
laboratory at MD Anderson Cancer Center, and grown in McCoy's SA medium 
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin and 
maintained at 37°C in a 5% C02 atmosphere. The MCF1 OA breast epithelial cells were 
also obtained from Dr. Adams and were cultured in Mammary Epithelial Basal Medium 
(MEBM) supplemented with a BulletKit (Clonetics) and maintained at 37°C in 5% C02. 
Both cell lines were prepared for the experiment by seeding 6 x 1 05 cells in chambered 
cover slips and allowing them 30 minutes to attach to the surface. The cells were rinsed 
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once with PBS before they were incubated with nanorod conjugates for 1 hour in 5% C02 
at 3 7°C. The LSPR peak absorbance of the nanorod conjugate solution was 1.5. Post the 
incubation, cells were rinsed 3 times with 1xPBS and then the appropriate cell media was 
added prior to imaging. The cells were imaged by TPL microscopy at SOX magnification 
with 780 nm illumination and 400-700 nm detection. 84 
KU7 bladder cancer cells were then grown in MEM medium supplemented with 
10% FBS and 1% penicillin-streptomycin and maintained at 37°C in a 5% C02 
atmosphere. The samples were prepared by seeding 4x105 cells on cover slips and 
allowing them to attach to the surface for 24 hours. Prior to treatment, the cell media was 
changed to OptiMEM and the GNR conjugates were for 4 hours. After the 4 hour 
incubation, the OptiMEM media was changed to MEM medium supplemented with 10% 
serum and incubated in 5% C02 at 3 7°C atmosphere for another 20 hours. Twenty 
minutes prior to fixation, the cells were rinsed once with warm PBS, then incubated with 
100 nM Alexa-488-wheat germ agglutinin (WGA) and left for 10 minutes in the cell 
incubator for WGA cellular internalization. After 10 minutes the cells were rinsed three 
times with warm PBS then fixed in 3.7% paraformaldehyde for 15 minutes and then 
washed three times with cold PBS and mounted on slides using Slow-Fade Antifade (all 
reagents were purchased from Molecular Probes). 
4.3.4 siRNA Plasmids construction 
The si-Genome On-Target, SMARTpool selection designed GAPDH-siRNA-
FITC were obtained from MD Anderson, in annealed, desalted, and 2'-hydroxyl form. 
The 3 '-Untranslated region (3 '-UTR) reporter plasmids for the siRNA were constructed 
via insertion of the hairpin GAPDH-siRNA-FITC sequence into the Bacteriophage 
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(pRNA)-U6.1/Neo/siRLuc, which is a GenScript siRNA expression vector. This 
expression vector is used for mammalian cell transfection and uses Renilla luciferase 
expression. The GAPDH-siRNA-FITC was inserted downstream of its U6 promoter, 
between the BamHI and Hindiii restriction sites as shown in Figure 4.1. The Liana 
Adams lab provided the Si-Genome On-Target plus Smart pool duplex sense and 
antisense sequences, these are listed in Table 4.1. The GAPDH-siRNA-FITC plasmid 
construct was inserted into the Luciferase vector into the BamHJ and Hindll/ restriction 
sites, using the associated restriction endonucleases, in the lOx SURE Cut Buffer B (100 
mM Tris-HCl pH 8.0, 50 mM MgCh, 100 mM NaCl, and 10 mM 2-Beta 
mercaptoethanol), and subjected to T4 DNA ligase using the lOX T4 DNA Ligase Buffer 
(300 mM Trish-HCl at pH 7.8, 100 mM MgCh, 100 mM DTT, and 10 mM ATP). The 
QIAquick DNA clean up systems from Qiagen was used for the plasmid construct. The 
pRNA-U6.1/Neo/siRLuc plasmid and GADPH-siRNA-FITC were obtained from MD 
Anderson, here 200 f..I.L of2 f..I.M GADPH-siRNA-FITC was added to 300 f..I.L ofthe 2 nM 
t-GNR-PEG-c-Ab with bound EGFR/C225, and mixed with a 1 mL aliquot of RNAse-
free buffer, the usual plasmid construction reaction was used above. 
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Figure 4-1. Bacteriophage (pRNA)-U6.1/Neo/siRLuc is a GenScript siRNA Renilla 
Luciferase expression vector. It was designed for mammalian transfection and uses a U6 
promoter for siRNA expression and BamHI and Hindlll sites. 
Table 4.1. The si-Genome On-Target, GAPDH SMART pool siRNA sense (left) and 
antisense (right) sequences were obtained from MD Anderson. 
siRNA encapsulation into the t-GNR-PEG-c-Ab plasmonic vector was achieved 
using PBS salt, which functions as an electrostatic shielding agent that neutralized the 
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PEG-COOH and siRNA charged entities. The shielding is based on a salting-in effect, 
which is a concentration and temperature dependant effect that imparts changes to the 
hydrophobic nature of the PEG. The combination of heat and salt affect the hydrogen 
bonding and water binding ability of the PEG allowing its water restructuring and 
amphiphilic properties to make it more hydrophobic. The salt bridges and temperature 
then alter the RNA charge, which promotes the RNA-PEG adsorption, and shielding, this 
is shown in Figure 4.2. 
t-GNR-PEG-c-Ab 
J 
siRNA 
GAPDH 
FITC Luc plasmid 
t-GNR-siRNA-P EG-c-Ah 
Figure 4.2. Encapsulating the siRNA-GAPDH-FITC-Luc plasmid was achieved by 
using the PBS salting-in effect, in combination with temperature, leading to the GNR 
plasmonic vector. The PBS and temperature were used to encapsulate the siRNA due to 
the hydration and charge changes that were imparted to the PEG and siRNA. 
The trypsinized and counted cells were diluted into an antibiotic-free complete 
medium to achieve the necessary seeding density in 100 J..LL solution and plated into 6 
well plates. The cells were incubated at 3 7°C with 5% C02 overnight. 
4.3.5 siRNA Trapping and Transfection 
The KU7 cells were incubated with t-GNR-siRNA-PEG-c-Ab complex in a 6-
well plate for 1 hour using Serum-free OptiMem. The conjugates were gently mixed and 
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heated for 4 minutes at 43°C, to this was added 3 mL of Opti-MEM (no serum) and 
conjugates were ready for cell transfection, this is shown in Figure 4.3. 
t-G N R·sl RHA-P EG-e·Ab 
FITC·GAPDH·siRNA 
OptiMf!-m SC!'rlum free media 
t•G N R·siRNA·PEG~Ab 
FITC·GAPDH·Sil RHA 
With bound C225 
OptiM&m Serum free media (HE PES) 
I!CU7 Bladder canur cells. 
------- ----- -----..- 2-4 hour int:ubation, 37ac S% C02 
Transfe.eted 
t·G NR·sl RNA-P£G;-c,.Ab 
FITC·GAPOH·siRNA 
With bound 025 
Then lasered 
Figure 4.3. Cell transfection of KU7 bladder cancer cells with the GNR-plasmonic 
vector. 
4.3.6 Cell Transfection 
A 500 J.!L aliquot of the 2 nM FITC labeled t-GNR-siRNA-PEG-c-Ab conjugates 
with bound C-225 were then added to Opti-MEM serum free media, and pipetted into 
each well for transfection of cancer cells. The resulting plasmonic vector was subjected 
to a two hour incubation at 3 7°C with 5% C02. Lipid transfection of KU7 cells was 
achieved using the DharmaFect (DF-1) General Transfection protocol system, where 2 
J.!M of GAPDH-siRNA-FITC was mixed into IX siRNA buffer and diluted into the DF-1 
transfection agent using serum-free media, and gently mixed. This was then incubated 
for 5 minutes at room temperature, followed by a 20-minute incubation in antibiotic free 
complete media. The culture media was then removed from the wells and 1 00 J.!L of the 
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appropriate DF-lipid-GAPDH-siRNA-FITC transfection vector was added to each well. 
The cells were incubated at 3 7°C in 5% C02 for 2 hours. 
4.3.7 siRNA Laser Release 
The plasmonic GAPDH-siRNA-FITC transfected cells were then subjected to 
laser treatment using a 1-Watt, 800 nm laser, which provided an energy density of 11.66 
Joules/cm2 (J/cm2). The conjugate-cell samples were irradiated for 60 seconds, and 5 
minutes using the fiber optic laser, at a height that was 3 em above the well. A schematic 
of the plasmonic prepared vector is shown below in Figure 4.4. After irradiation, the 
samples were incubated for 48 hours with 2 mL of full-serum media Opti-Mem, and 
analyzed by 
Reverse Transcriptase Polymerase Reaction (RT-PCR). 
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Figure 4.4. Schematic illustration of the GNR-PEG-COO-Ab-siRNA targeted carriers 
with energy controlled release of genes into cancer cell line. The GNR are coated with a 
biocompatible PEG polymer, and EGFR conjugated peptides. 
4.3.8 RT-PCR 
Measurement of GAPDH-mRNA was achieved using RT-PCR. Total RNA was 
extracted using a Minerva extraction reverse transcription kit (Applied Biosystems) and 
10 ng of RNA along with GAPDH specific primer siRNA were used for expression 
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analysis, using a 18S ribosomal RNA as an internal control. eDNA was synthesized 
using First Choice RACE-Ready eDNA kit. RT-PCR was performed using the PCR 
program on ABI prisms SDS 7000 (Applied Biosystems). KU7 cells were incubated with 
non-targeting Glyceraldehyde (NTG) and GAPDH-targeted GNR for 48 hrs. The RNA 
was extracted and GAPDH-mRNA was measured. 
4.3.9 Imaging methods 
Various microscopic methods were used to image the internalized GNR in the 
cancer cells. Confocal imaging was carried out using the Leica SPRSRS AOBS 
microscope with a 63x/1.4 objective. GNR were detected at 633 nm illumination in 
reflection mode. Unmodified TPL microscopy was conducted at SOX with 780 nm 
illumination, and 400-700 nm detection. Bioconjugates were also analyzed in a Horiba 
Jobin-Yvon FluoroLog-3 fluorimeter with CW Xenon excitation. TEM was conducted at 
MD Anderson's High Resolution Electron Microscopy Facility (HREMF) using standard 
fixation and embedding of cells on a JEMIOIO transmission electron microscope (TEM). 
4.4 Results and Discussion 
4.4.1 N anorod conjugation 
Protein and peptide conjugation to the GNR was carried out using commercially 
available functionalities, which strongly bind gold surfaces. To deliver the nucleic acid 
material to the specific tissue, the GNR were bound to monoclonal antibodies. In our 
strategy, we started out by PEGylating the GNR with a t-PEG-c linker to attach 
antibodies to the nanorod surface. These t-GNR-PEG-c conjugates were then coupled to 
antibodies by standard NHS-EDC carbodiimide chemistry. EGFR-C225, a disulfide-
bond containing peptide, was the first choice for GNR-peptide conjugation because 
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EGFR is over-expressed in superficial bladder cancers. 120 We used a conjugation scheme 
where the antibody was placed on the outside of the PEG layer by using a PEG carboxyl 
group at the free end, this is shown in Figure 4-5. 
EDC 
eN 
' 
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Figure 4-5. GNR bioconjugation strategy, with NHS-EDC, and subsequent antibody 
binding. 
The EDC carbodiimide chemistry activated the carboxylate end groups of the 
PEG-COOH which allowed for the PEG-antibody functionalization through NHS. The 
NHS stabilized amine reactive acylisourea intermediate created an NHS ester that could 
form an amide bond with the hydrophobic amine of the antibody. 125•56 This resulted in a 
complex containing a GNR that was 50 nm long and 15 nm in diameter, a PEG-COO-
coating (5,000 Dalton) with antibody bound at the end groups that was 30 nm in length, 
and unreacted hydrophilic COOH groups with a Debye length that was 1 nm. Salt 
screening of any non-antibody containing COOH-PEG molecules allowed for the fine 
tailoring of the electrostatics of the GNR-PEG-COO-Ab complex. 125 The conjugation of 
the C225 antibody was pursued, as this targets EGFR expressing cells and tissues which 
are frequently found in human bladder cancers that exhibit chemotherapy resistance. 120 
The down regulation of EGFR has shown to reverse malignancy in bladder cancer 
. d d . b . . 1 h d 120 associate tumors an IS eing active y researc e . 
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4.4.2 Fluorimetry 
To visualize the cellular internalization of the GNR coupled with the anti-EGFR 
blocking antibody EGFR-C225, we labeled the conjugates with anti-rabbit IgG carrying 
an Alexa Fluor-488 dye (AF-488-IgG) and developed simple analytical assays to test for 
successful conjugation, this is shown in Figure 4-6. During conjugation, the GNR had a 
concentration of 1 nM while the AF-488-IgG had a concentration of 200 nM and 
therefore the fluorescence of the resulting solution was dominated by free AF-488-IgG. 
Subsequent rounds of centrifugation produced decants with increasingly lower 
concentrations of free AF-488-IgG yielding a lower sample fluorescence, until the signal 
reached the noise level. Following the centrifugation and decantation steps, the 
fluorimetry of the resuspended pellet was found to be equivalent to the 3rd decant. The 
fluorescence from the AF -488-IgG bound to the GNR indicated a concentration on the 
order of 1 nM, suggesting that approximately 2 IgG molecules were bound to each GNR, 
which is reasonable considering their small size. The results of this measurement 
represent actually a lower limit since the fluorescence signal of the GNR solution is 
reduced due to the absorption of the GNR. 132 
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Fluorimetry of G R-PEG-COO-Ab Conjugates 
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Figure 4-6. Fluorimetry data comparing nanorod conjugates with decants, following 
several rounds of centrifugation to reduce unbound antibody and CT AB concentrations. 
4.4.3 Zeta Potential 
Electrokinetic analysis was used to monitor the reduction and purification of the 
CTAB conjugates. Table 4-2 lists the zeta potential of CTAB stabilized GNR, t-GNR-
PEG-c conjugates, and fmally the AF-488-IgG conjugated to the t-GNR-PEG-c-Ab 
bioconjugates. The positive and negative values for cationic CT AB and anionic COOH-
PEG were expected due to changes to the GNR surface chemistry. Upon antibody 
conjugation, the zeta potential change to -5 ± 2 m V suggesting the binding of the 
antibody molecule at the surface of the GNR, this is shown in Table 4-2. The expected 
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value is difficult to pin down, since lgG isoelectric points (Pis) vary significantly and this 
experiment was carried out with polyclonal antibodies. However, the zeta potential data 
confirms that a molecular change at the surface of the GNR conjugates occurred due to 
the antibody binding. 
Nanoparticle 
GNR-CTAB 
GNR-S-PEG-COOH 
GNR-S-PEG-IgG 
Zeta Potential (mY) 
+85±2 
-19±2 
-5±2 
Table 4-2. Zeta potential of antibody GNR conjugates. 
4.4.4 Cell-specific Internalization 
The confocal analysis of the KU7 bladder cancer cells that were treated with the 
10 nM t-GNR-PEG-c-Ab conjugates with bound C225, and stained with a DNA-specific 
dye, Alexa-633-Topro3 (blue pixels), is shown in Figure 4-7, left panel. GNR were 
detected with 633 nm illumination in reflection mode, and Wheat Germ Agglutinized-
AF-488 (WGA-AF-488) was excited at 488 nm and detected at 495-530 nm. It is notable 
that a non-specific Alexa-488 labeled WGA-IgM antibody coupled to the GNR did not 
show cellular internalization using this imaging method, Figure 4-7, right panel. 
Importantly, KU7 cells that are resistant to the EGFR blockade, either by antibodies or 
small inhibitory molecules such as Iressa, are still displaying the internalized GNR 
complexes that are expressing the EGFR protein. 121 
75 
Figure 4-7. Confocal analysis of KU7 cells treated with 10 nM C225-conjugated 
GNR. The C225 (left panel) and non-specific IgM (right panel) antibodies were labeled 
with Alexa-488 fluorochrome, The KU7 cells were fixed in paraffin (3.7%), and nuclei 
were stained using a DNA die, Topro-3 labeled with the Alexa-633 fluorochrome 
(Molecular Probes). Both panels show the merged images from both channels. 
4.4.5 TEM 
A complimentary technique such as Transmission Electron Microscopy (TEM) 
was used to image the particles inside the cells. UMUC5 cells treated with GNR coupled 
to C225, are shown in Figure 4-8, left-lower panel, red circle. The UMUC5 cell line is 
one of the most sensitive cells lines to the EGFR blockade tested by the Adams lab thus 
far. 122 The naked GNR were internalized by the mouse 3T3 fibroblasts in lysosomes and 
thus prone to immediate degradation through a non-specific pathway, this is shown in 
Figure 4-8, lower right panel. By contrast, the C225-targeted GNR do not appear to 
reside inside well-defined structures, such as lysosomes, but they were found free in the 
cytoplasm of cells, close to the ribosomal cell-transcription machinery. These ribosomes 
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can be easily identified along the endoplasmic reticulum (ER), giving the rough ER. The 
differences in the targeted GNR subcellular locations are due to internalization 
mechanisms that initially follow an active pathway through EGFR internalization, and 
later undergo a passive mechanism that is of lesser amplitude. The location of the GNR in 
each case was different, especially since the GNR were engineered to be cargos for non-
coding RNAs (ncRNAs). This strongly suggested that the use non-specific antibodies or 
naked GNR would result in ncRNA degradation through lysosomes. 
Figure 4-8. TEM shows that the size of the particles is very similar to components of a 
cellular ribosome, Rhybo. 
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4.4.6 Internalization of siRNA Plasmonic Vector 
The overall goal of this study was to introduce siRNAs into somatic cells and 
provide additional biologic functions as well as to stop the production of detrimental 
genes implicated in the resistance to EGFR-targeted therapy in bladder cancer cell lines. 
Compared with viral vectors, synthetic gene-delivery systems such as liposomes and 
polymers, offer several advantages, including ease of production and reduced risk of 
cytotoxicity and immunogenicity, but their use has been limited by the relatively low 
transfection efficiency and their lack of specificity. These problems are mainly due to the 
difficulty in controlling properties at the nanoscale. Our application focuses on using a 
non-viral gene delivery system based on biocompatible plasmonic GNR. This plasmonic 
vector can simultaneously bind nucleic acid sequences encoding for specific siRNAs and 
targeting antibodies in order to release the functional material in the targeted cells. This 
approach will allow for the precise control of composition, size and multi-functionality of 
the delivery system. To determine whether siRNA could also be delivered into cancer 
cells, we used an original protocol in which the FITC labeled t-GNR-siRNA-PEG-c-Ab 
conjugates with bound C225 are formed at 43 oc and then delivered into cells by direct 
incubation and receptor mediated endocytosis. Since the internalized GNR can be 
tracked by using fluorophore-labeled antibodies or nucleic acids, we decided to exploit 
the light scattering of the GNR. Their exposure to 700-800 nm light could be used as a 
method of tracking GNR in cells and tissues, Figure 4-9, right panel, arrows. In this 
experiment, the cells were incubated and targeted with t-GNR-PEG-c-Ab with bound 
C225, and immediately imaged using 800 nm TPL at different time points to estimate the 
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degree of GNR integration. We also used fluorochrome labeled antibodies (anti-EGFR, -
AXL or -non-specific IgG) coupled to the GNR to determine whether the GNR were 
internalized through an active or a passive mechanism into the cells. The GNR 
internalization was tracked in KU7 cells using organelle-specific fluorochrome dyes and 
chemical inhibitors to determine which pathway is responsible for the active GNR 
internalization. Intracellular trafficking was studied using the Lysotracker (lysosomes) 
· and membrane dyes, such as Die-I and Sito-9 live cell imaging. 
Figure 4-9. TPL of nonspecific IgG-GNR (red pixels). Alexa-488 labeled WGA was 
added to live bladder mesenchymal UC3 cells cell 10 min before fixation Alexa-488 
WGA with C225-GNR seen in red (far right), and Alexa488-WGA in green no GNR 
(lower left). 
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Confocal microscopy Images of KU7 cells exposed to the t-GNR-PEG-c-Ab 
conjugated to the EGFR/C225-Fluorescein isothiocyanate (FITC) and controls are shown 
in Figure 4-10. EGFR/C225 was chosen as port of entry into the cells because its 
expression level is high in bladder cancer cells compared with normal urothelium. 
EGFR-mediated cell internalization occurs through a well-known mechanism involving 
the endosomal pathway which is a form of active transport. 120-123,126 
MERGE NRIC225* Ph-EGFR 
Ph-EGFR 
NRJC225* 
II DNA 
Figure 4-10. Confocal microscopy of KU7 Cells shown (top left) NR-C225-EGF, 
(middle top) NR-C225, (top right) Phenyl red-EGFR, (bottom left) EGF control, (bottom 
right) C225-EGF control. Green images shown GNR binding in KU7 cells with and 
without EGF, DNA is shown in blue. 
To compare the FITC-siRNA transfection and its ability to achieve endosomal 
release and gene silencing, we used a charge neutral plasmonic transfection system 
composed of the FITC labeled t-GNR-siRNA-PEG-c-Ab bound to C225 and compared it 
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to a cationic liposome-based Dhannafect (DF-1) transfection reagent from Dhannacon 
shown in Figure 4-11. Lipid-mediated transfection which is common to siRNA delivery 
is most often used, however, it can be problematic as many cell types may suffer from 
chemical, cytotoxic and immunological shock in reaction to exposure to cationic lipid 
reagents. 96•102•119 This often makes it necessary to use DF-1 reagents, which overcome 
these limitations in hard-to-transfect cell types. 127 DF-1 allows for the successful 
delivery of GAPDH-siRNA-FITC with low toxicity, and can achieve robust siRNA 
uptake for gene silencing. Our results showed that lipid transfection was minimally 
successful in delivering GAPDH-siRNA-FITC into the cells, however, this did not 
' 
compare to the plasmonic FITC labeled t-GNR-siRNA-PEG-c-Ab complex which 
evidenced higher internalized bioconjugates, Figure 4-11 lower left. The controls of the 
GNR-siRNA-FITC and siRNA-FITC show no internalization, when compared to the t-
GNR-siRNA-PEG-c-C225 bioconjugates. These results indicated that the physical and 
chemical interactions between the t-GNR-PEG-c-C225 complex and the GAPDH-
siRNA-FITC could be easily manipulated within physiological temperature ranges. 
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Figure 4-11. Cellular integration of bi-functionalized gold nanoparticles as observed 
by confocal. The images of live cells were taken 12 hrs post-transfection using a 40x 
objective-Zeiss Observer-Zl. 
4.4. 7 Plasmonic Vector Trapping/Release 
The t-GNR-PEG-c-Ab plasmonic vector kinetically trapped the GAPDH-siRNA-
FITC in the PEG polymer layer, to protect the GAPDH-siRNA-FITC for its 
internalization and release inside the cell. To overcome additional physical barriers such 
as receptor-mediated endocytosis, a PEG shield was included to reduce nonspecific 
binding and C225 was used as the targeting antibody. The PEG-COOH end groups were 
then salt screened using the cations from the PBS buffer leading to salt bridge formation. 
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125
•
128
"
129 A thermally induced gradient from the heating block then allowed for the 
kinetic trapping of the GAPDH-siRNA-FITC material. This combined temperature 
increase and salt screening was able to alter the structure of the PEG-COO- layers by 
changing the H-bonding network, and with it the degree of hydration. 128"129 Increased 
temperature activated the flow, or pour point of the PEG which occurs around the glass 
transition temperature of 35-40-45°C, leading to a liquid-like structure, with melting of 
the PEG polymer which occurs at 50-60°C, being avoided. 128"129 An attractive force 
between PEG chains occurs at 43°C leading to a reduction in the repulsive forces, which 
decreases the number of bound water molecules onto the inert hydrophilic polymer 
chains. Structural changes brought about by heat also affect the GAPDH-siRNA-FITC, 
which likewise undergoes dehydration, and structure rearrangement. The combined 
temperature and salt screening allows for the encapsulation of the siRNA. With an 
equilibration to 25°C the hydrophilic PEG chains are again able to bind water molecules, 
thereby shielding the encapsulated siRNA. Numerous methods such as temperature, laser 
heating, ionization, salt, and pH can be used to bring about structural changes to the PEG 
layers which alter the number of water cages and degree of hydration. 128"129 This can be 
of interest for the drug delivery of encapsulated pharmaceutical agents. 
4.4.8 NIR Laser Heating 
Following incubation, the GNR underwent receptor-based endocytosis into its 
targeted intracellular compartments, and were irradiated by a non-collimated NIR laser 
light to locally heat and release the genetic material within the cells. Activation of the 
PEG pour point would cause the trapped GAPDH-siRNA-FITC to be released into a 
medium were electrostatic screening from a high salt media was lacking. This allowed 
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the GAPDH-siRNA-FITC to be released into the cytoplasm and ensuing cytosol for 
subsequent protein inactivation through mRNA silencing. The laser output power was 
optimized to accomplish the desired degree of NIR irradiation and subsequent plasmon 
heating by the GNR, namely 45°C, which in turn controls the extent of the GAPDH-
siRNA-FITC release. Laser settings can be optimized such that the target tissues and 
therapeutic oligonucleotide molecules are not negatively affected.104 On the basis of the 
preliminary results, we show that the photothermal strategy is able to successfully release 
GAPDH-siRNA-FITC from the PEG-NR-C225 complexes, at specific power density 
parameters and irradiance settings, this is shown in Figure 4-11. 
4.4.9 RT-PCR 
To determine whether the RNA released from the GNR after NIR exposure is 
functional, we exposed cells to GAPDH-siRNA-FITC which was targeted to the GAPDH 
gene, and exposed the cells to a low-power non-collimated NIR laser. After 48 hours we 
measured the GAPDH-mRNA expression by real-time RT -PCR. The GAPDH gene is 
ideal for optimizing siRNA transfection conditions by helping to confirm that 
transfection procedures and cell cultures support gene silencing. Furthermore, GAPDH 
expression is actively correlated with tissues and cell types that differentially express the 
EGFR receptor. The down-regulation of the GAPDH gene is highly relevant for bladder 
cancer as it is up-regulated in malignant cancer cells and can be down-regulated by 
cancer based therapies. Changes to the expression of the GAPDH-mRNA are therefore 
highly relevant to bladder cancer-based gene therapies. The results shown in Figure 4-12 
demonstrate that NIR exposure resulted in a minimal reduction of GAPDH expression 
with no cell death evidenced, whereas cells that were not exposed to NIR showed no 
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change in GAPDH levels (Figure 4-12, white boxes). This signifies that some gene 
silencing of GAPDH-mRNA is occurring with the laser-treated, FITC labeled t-GNR-
siRNA-PEG-c-Ab particles. The FITC labeled t-GNR-siRNA-PEG-c-Ab conjugates were 
able to confirm that the transfection procedure achieved moderate gene silencing 
following laser GAPDH-siRNA-FITC delivery inside the bladder cancer cell lines, 
without achieving any cell damage. Therefore, future studies that are more optimized 
would be needed to silence the gene further. 
85 
r- II No NIR 
38 D+NIR 
rtt37 
z 
-ps 
~5 
IL 
r f3 .. 
i32 
E 
031 
z 
30 
-
NTG siGAPDH 
Figure 4-12. Measurement of GAPDH-mRNA using real-time RT-PCR. KU7 cells 
were incubated for 48 hours with non-targeting Glyceraldehyde (NTG) and GAPDH 
targeted siRNA-FITC that was housed with the t-GNR-PEG-Ab with C225. The RNA 
was extracted and GAPDH-mRNA was measured. The mRNA normalization was done 
by measurement of 18S ribosomal RNA (internal control). 
4.4.10 Plasmonic Vector Discussion 
The goal of gene therapy is to introduce foreign genes into somatic cells and 
provide additional biological functions to stop the production or function of detrimental 
genes. This can be achieved using various vector based delivery methods. Compared to 
viral vectors, synthetic gene-delivery systems (such as liposomes and polymers) offer 
several advantages, including ease of production and a reduced risk of cytotoxicity and 
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immunogenicity, but their use is often limited by the relatively low transfection 
efficiency and nonspecificity. These problems are mainly due to the difficulty in 
controlling their properties at the nanoscale. Our application used a targeted non-viral 
gene delivery system based on biocompatible GNR plasmonic vector that could 
simultaneously trap the GAPDH-siRNA-FITC, and used the targeting of C225 antibodies 
to ensure the delivery and cytoplasmic release of the functional siRNA material inside the 
endosomal compartments. This approach allowed for the precise control of composition, 
size and multifunctionality of the gene delivery system, which could be assayed with 
microscopic, fluorescence, zeta potential, TPL, and RT-PCR methods. The FITC labeled 
t-GNR-siRNA-PEG-c-Ab vector, whose size is below 100 nm, used a PEG shield to 
enhance the GAPDH-siRNA-FITC delivery. Furthermore the PEG-C225 antibody 
targeted delivery vehicle allowed for receptor-mediated endocytosis into its appropriate 
endosomal compartment. The GAPDH-siRNA-FITC was trapped by temperature 
increases in the hydrophilic, salt screened PEG layer resulting from the use of a heating 
block, while the release of the siRNA resulted from laser treatment and subsequent NIR 
plasmons in the GNR. The resulting plasmonic vector was able to achieve successful 
delivery when compared with the DF-1 liposome vector and modest gene silencing of the 
GADPH housekeeping genes was confirmed by RT-PCR. Thus, we have produced a 
proof of concept experiment where a suitable transfection with a targeted plasmonic 
FITC labeled t-GNR-siRNA-PEG-c-Ab vector can be further optimized to ensure 
silencing of the GAD PH housekeeping gene, as well as other bladder cancer associated 
genes. 
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4.5 Conclusion 
An untreatable form of bladder cancer was studied using the t-GNR-PEG-c-Ab 
bioconjugates with C225 antibody. The t-GNR-PEG-c-Ab were used to create as 
plasmonic vector that housed a GAPDH-FITC labeled siRNA, termed GAPDH-siRNA-
FITC, which was included within a Luciferase based plasmid. A salt based electrostatic 
heating method was used to trap the GAPDH-siRNA-FITC from the PEG layer by 
activating the PEG polymer pour point, while a laser based heating system was used for 
in vitro release inside cancer cells. The down regulation of the GAPDH gene was 
targeted by the siRNA, as GAPDH has been shown to be up-regulated in many cancers 
and down-regulated by chemotherapeutic drugs. Cell culture, and subsequent imaging by 
TEM, TPL and confocal microscopy were used to view the internalized conjugates, and 
RT-PCR were used to determine if the release of the GAPDH-siRNA caused a reduction 
in the expression of GAPDH-mRNA. Plasmonic gene silencing of the gene by the 
GAPDH-siRNA was then compared to a lipid based Dharmafect control in terms of 
transfection ability, and suggested that the plasmonic vector was a more optimal choice. 
88 
CHAPTERS 
Conclusions 
The material surface properties of gold nanoparticles govern interactions at visible 
and NIR wavelengths, which lead to the ability to manipulate light at the nanometer 
scale. The gold nanoparticles can then manipulate light through resonant collective · 
oscillations of the conduction electrons, which are LSPR that result in strong optical 
absorption and scattering, at visible and NIR wavelengths. This can be of considerable 
interest in biomedical applications, since the plasmon resonances can affect localized 
heating and light scattering, which can benefit biological systems that require relatively 
inert gold nanoparticle based therapies. The CT AB-gold absorption is quite strong and it 
is often difficult to remove the bound CTAB, which is problematic for in vivo, cell-based 
applications. Chloroform extractions of CT AB showed that a critical CT AB/GNR ratio 
is needed in order to maintain colloidal stability of the GNR, this was found to be 
740,000:1. mPEG(sooo)-SH functionalization was shown to displace the CT AB while 
polyelectrolytes can wrap the CTAB present on the surface of the GNR. Both the 
mPEG(sooo)-SH and PSS stabilization methods were effective methods by which to 
stabilize the GNR. However, the mPEG(sooo)-SH covalent functionalization method leads 
to higher yields and more monodisperse GNR samples. Yet in spite of mPEG(sooo)-SH 
covalent functionalization methods, some residual CT AB remains bound to the particles, 
as shown by the MS data. Nevertheless at these CT AB concentrations, which are below 
1 0 J.!M, cell cytotoxic effects are typically absent. 
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GNR targeting experiments were successfully carried out with stable 
bioconjugates that resulted from the use ofNHS-EDC chemistry and a bifunctional PEG 
with thiol and carboxyl end groups. This resulted in the formation of an amide bond 
between the linker and antibody, and the strong-gold thiol bond between the linker and 
GNR. The carbodiimide linking strategy was successful in producing carboxy-terminal 
PEGylated GNR that could undergo successful bioconjugation with antibodies. 
Furthermore this conjugation strategy was reproducible despite the strength of the 
original gold-CT AB interaction. Zeta potential measurements were able to confirm 
changes to the intended surface chemistry, leading to negative potentials for the carboxy-
terminated GNR conjugates and near-neutral charge for the zwitterionic antibody protein 
GNR bioconjugates. Fluorimetric assays suggested that two antibodies per nanorod were 
present and Nanoparticle ELISA assay demonstrated that a large fraction of these bound 
antibodies were active. Successful in vitro targeting of the GNR bioconjugates was 
shown in two cell types using the HER-2 and C225 antibodies. TPL and confocal 
reflectance were then used to successfully image the t-GNR-PEG-c-Ab particles that 
were successfully internalized by the cells. 
Our gene therapy application used a targeted nonviral gene-delivery system based 
on biocompatible GNR that could simultaneously trap GAPDH-siRNA-FITC and used 
the targeting of C225 antibodies to ensure the delivery and cytoplasmic release of the 
functional siRNA material. The FITC labeled t-GNR-siRNA-PEG-c-Ab vector, used a 
PEG shield to enhance the GAPDH-siRNA-FITC delivery. Furthermore the PEG-C225 
antibody targeted delivery vehicle allowed for receptor-mediated endocytosis into its 
appropriate endosomal compartment. The GAPDH-siRNA-FITC was trapped by 
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temperature increases in the hydrophilic salt screened PEG layer resulting from the use of 
a heating block, while the release of the siRNA resulted from laser treatment and 
subsequent NIR plasmons in the GNR. The resulting plasmonic vector was able to 
achieve successful delivery when compared with the DF-1 liposome vector and modest 
gene silencing of the GADPH housekeeping genes was confirmed by RT-PCR. Thus, we 
have produced a proof of concept experiment where a suitable transfection with a 
targeted plasmonic FITC labeled t-GNR-siRNA-PEG-c-Ab vector can be further 
optimized to ensure silencing of the GADPH housekeeping gene, as well as other bladder 
cancer associated genes. This approach allowed for the precise control of composition, 
size and multifunctionality of the gene-delivery system, which could be assayed with 
microscopic, fluorescence, zeta potential, TPL, and RT-PCR methods. 
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